<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer - Zaheed, M - 2019 | Cochrane Library</title> <meta content="Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer - Zaheed, M - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer - Zaheed, M - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012873.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer" name="citation_title"/> <meta content="Milita Zaheed" name="citation_author"/> <meta content="Concord Repatriation General Hospital" name="citation_author_institution"/> <meta content="Nicholas Wilcken" name="citation_author"/> <meta content="Melina L Willson" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="Dianne L O'Connell" name="citation_author"/> <meta content="Cancer Council NSW" name="citation_author_institution"/> <meta content="Annabel Goodwin" name="citation_author"/> <meta content="Annabel.Goodwin@health.nsw.gov.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012873.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/02/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012873.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anthracyclines [*administration &amp; dosage, adverse effects]; Antibiotics, Antineoplastic [*administration &amp; dosage, adverse effects]; Antineoplastic Agents [*administration &amp; dosage, adverse effects]; Breast Neoplasms [*drug therapy, mortality, pathology]; Chemotherapy, Adjuvant; Cyclophosphamide [administration &amp; dosage, adverse effects]; Disease-Free Survival; Docetaxel [administration &amp; dosage, adverse effects]; Doxorubicin [administration &amp; dosage, adverse effects]; Drug Administration Schedule; Epirubicin [administration &amp; dosage, adverse effects]; Fluorouracil [administration &amp; dosage, adverse effects]; Neoadjuvant Therapy; Nervous System [drug effects]; Neutropenia [chemically induced]; Paclitaxel [administration &amp; dosage, adverse effects]; Quality of Life; Randomized Controlled Trials as Topic; Taxoids [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012873.pub2&amp;doi=10.1002/14651858.CD012873.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012873\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012873\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ja","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012873.pub2",title:"Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer",firstPublishedDate:"Feb 18, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012873.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012873.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012873.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012873.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012873.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012873.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012873.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012873.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012873.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012873.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9410 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012873.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-sec-0116"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/appendices#CD012873-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/table_n/CD012873StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/table_n/CD012873StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#CD012873-cr-0002">Milita Zaheed</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#CD012873-cr-0003">Nicholas Wilcken</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#CD012873-cr-0004">Melina L Willson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#CD012873-cr-0005">Dianne L O'Connell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information#CD012873-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Annabel Goodwin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information/en#CD012873-sec-0134">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 February 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012873.pub2">https://doi.org/10.1002/14651858.CD012873.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012873-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012873-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012873-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012873-abs-0001" lang="en"> <section id="CD012873-sec-0001"> <h3 class="title" id="CD012873-sec-0001">Background</h3> <p>Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline‐based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment of early breast cancer. </p> </section> <section id="CD012873-sec-0002"> <h3 class="title" id="CD012873-sec-0002">Objectives</h3> <p>To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. </p> </section> <section id="CD012873-sec-0003"> <h3 class="title" id="CD012873-sec-0003">Search methods</h3> <p>We searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 1 February 2018. </p> </section> <section id="CD012873-sec-0004"> <h3 class="title" id="CD012873-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing administering a taxane prior to an anthracycline with taxane following anthracycline to people with early breast cancer receiving chemotherapy. The studies needed to have reported on at least one of our outcomes of interest, which included overall survival, disease‐free survival, pathological response, treatment adherence, toxicity and quality of life. </p> </section> <section id="CD012873-sec-0005"> <h3 class="title" id="CD012873-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data, assessed risk of bias and quality of the evidence. The primary outcome measure was overall survival. Secondary outcomes included disease‐free survival, pathological response (in the neoadjuvant setting only), adverse events, treatment adherence and quality of life. For time‐to‐event outcomes of overall survival and disease‐free survival, we derived hazard ratios (HRs) with 95% confidence intervals (CI) where possible. For dichotomous outcomes of pathological complete response, treatment adherence and adverse events, we reported the treatment effect as a risk ratio (RR) with 95% CI where possible. We used GRADE to assess the certainty of the evidence separately for the neoadjuvant and adjuvant settings. </p> </section> <section id="CD012873-sec-0006"> <h3 class="title" id="CD012873-sec-0006">Main results</h3> <p>There were 1415 participants in five neoadjuvant studies and 280 participants in four adjuvant studies involving five treatment comparisons. Four of the five neoadjuvant studies collected data for the primary outcome (overall survival) and two studies had data available; one of the four adjuvant studies collected overall survival data. </p> <p>The neoadjuvant studies suggested that the administration of taxanes first probably resulted in little to no difference in overall survival (HR 0.80, 95% CI 0.60 to 1.08; 947 participants; 2 studies; moderate‐certainty evidence) and disease‐free survival (HR 0.84, 95% CI 0.65 to 1.09; 828 participants; 1 study; moderate‐certainty evidence). Administration of taxanes first also resulted in little to no difference in pathological complete response (absence of cancer in the breast and axilla: RR 1.15, 95% CI 0.96 to 1.38; 1280 participants; 4 studies; high‐certainty evidence). However, there appeared to be a trend in favour of taxanes first. Studies reported treatment adherence using a range of measures. Administration of taxanes first probably did not increase the likelihood of requiring dose reductions compared to administration of anthracyclines first (RR 0.81, 95% CI 0.59 to 1.11; 280 participants; 1 study; moderate‐certainty evidence). There was probably little to no difference in the risk of grade 3/4 neutropenia (RR 1.25, 95% CI 0.86 to 1.82; 280 participants, 1 study; moderate‐certainty evidence) or grade 3/4 neurotoxicity (RR 0.95, 95% CI 0.55 to 1.65; 1108 participants; 2 studies; low‐certainty evidence) when taxanes were given first. There were no data on quality of life. </p> <p>Only one adjuvant study collected data on overall survival and disease‐free survival but did not report data. Administration of taxanes first reduced the risk of grade 3/4 neutropenia (RR 0.62, 95% CI 0.40 to 0.97; 279 participants; 4 studies, 5 treatment comparisons; high‐certainty evidence) and appeared to result in little to no difference in grade 3/4 neurotoxicity (RR 0.78, 95% CI 0.25 to 2.46; 162 participants; 3 studies; low‐certainty evidence). There was probably little to no difference in the proportions experiencing dose delays when taxanes are given first compared to anthracyclines given first (RR 0.76, 95% CI 0.52 to 1.12; 238 participants; 3 studies, 4 treatment comparisons; moderate‐certainty evidence). One study reported on quality of life and indicated that scores (using the Functional Assessment of Cancer Therapy – Breast Cancer (FACT‐B) validated questionnaire) were similar in both groups though did not provide numerical data. </p> </section> <section id="CD012873-sec-0007"> <h3 class="title" id="CD012873-sec-0007">Authors' conclusions</h3> <p>In the neoadjuvant setting, there is high‐ to low‐certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease‐free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full‐text publication of a relevant neoadjuvant study for women with HER2‐negative breast cancer for inclusion in an update of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012873-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012873-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012873-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012873-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012873-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012873-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012873-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012873-abs-0003" lang="en"> <h3>Taxane chemotherapy before or after anthracycline chemotherapy in early breast cancer</h3> <p>Anthracyclines and taxanes are active classes of chemotherapeutic agents used before or after surgery for early breast cancer. </p> <p><b>What is the aim of this review?</b> </p> <p>We aimed to find out if giving people with early breast cancer (where the cancer has not spread beyond the lymph nodes near the breast) taxane chemotherapy before anthracycline chemotherapy (instead of after) would change outcomes. </p> <p>While the benefits of adding taxanes to anthracyclines are well established, it is unknown whether giving taxane chemotherapy before or after anthracycline chemotherapy has an impact on how long people live, how long they remain free of breast cancer, their completion of treatment, the side effects of treatment and their quality of life. </p> <p><b>Key messages from the review</b> </p> <p>The order in which taxane and anthracycline chemotherapies are given may have had little to no impact on:<br/> – how long participants lived;<br/> – how long they remained free of breast cancer;<br/> – completion of treatment and<br/> – side effects of treatment. </p> <p>None of the studies reported data on quality of life. Many of the studies did not report information on important outcomes such as how long people will live or remain free of breast cancer. We await the publication of one relevant study involving 112 participants who receive chemotherapy before breast cancer surgery for inclusion in an update of this review. </p> <p>In summary, the results found no sufficient evidence of benefit or harm due to the order in which taxane and anthracycline chemotherapies are given. In most institutions, standard practice would be to deliver anthracycline followed by taxane. Based on this review of the evidence, the currently available data do not support a change in this practice. </p> <p><b>What was studied in the review?</b> </p> <p>For women with early breast cancer who have a higher risk of cancer returning, combination chemotherapy with anthracycline and taxane is often offered either before or after surgery to reduce the risk of cancer returning and prolong life. Traditionally, anthracyclines are given first followed by taxanes but there is no strong evidence for this order. We compared the possibility of giving taxanes first followed by anthracyclines compared to the standard treatment with anthracycline first. </p> <p><b>What are the main results of the review?</b> </p> <p>All participants in the studies were women. We found five studies involving 1415 participants in which chemotherapy was given prior to surgery. The taxane medicine used in three of these studies was paclitaxel, while the other two studies used docetaxel. Two studies used a single agent anthracycline (epirubicin), while three studies used a combination of epirubicin, cyclophosphamide and fluorouracil. There were also four studies involving 280 participants that compared the order of giving taxanes and anthracyclines to participants who were receiving chemotherapy after breast cancer surgery. The taxane used in all four studies was docetaxel, while the anthracyclines used were a combination of epirubicin or adriamycin plus either cyclophosphamide or fluorouracil (or both). </p> <p>The main results were that the order in which taxane chemotherapy is given:</p> <p>– probably resulted in little to no difference in survival or risk of cancer coming back for participants who receive chemotherapy before surgery; </p> <p>– probably resulted in little or no difference in the degree by which the tumour may have shrunk in response to chemotherapy for participants who received chemotherapy before surgery; </p> <p>– may have resulted in little or no difference in having side effects for participants receiving chemotherapy before surgery but giving taxanes first reduced the risk of neutropenia (low white blood cell count) in those who received chemotherapy after surgery. The side effects that were examined were neutropenia and neurotoxicity (damage to the nerves); </p> <p>– probably resulted in little to no difference in the proportion of participants receiving chemotherapy after breast cancer surgery experiencing delays in chemotherapy doses. </p> <p>Many studies did not collect or report data on survival, the risk of cancer coming back or overall well‐being (quality of life). In some cases, the studies did not report data that could be used in the review and we wait for responses from the investigators who conducted the trials. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to February 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012873-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-sec-0122">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-sec-0187">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012873-sec-0122"></div> <h3 class="title" id="CD012873-sec-0123">Implications for practice</h3> <section id="CD012873-sec-0123"> <p>This review has not found significant evidence of benefit or harm due to the sequence in which taxane is delivered. In most institutions standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full‐text publication of one study in the neoadjuvant setting that will report on important outcomes (i.e. pathological complete response, and overall and disease‐free survival) that will help to answer this review question (<a href="./references#CD012873-bbs2-0027" title="BinesJ , KestelmanF , SivaSB , SarmentoRMB , SmallIA , RodriguesFR , et al. Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial. Journal of Clinical Oncology2018;36(15):575. NCT012700373 . NeoSAMBA neoadjuvant: does the sequence of anthracycline and taxane matter: before or after?. clinical.tirals.gov/show/NCT01270373 (first received 5 January 2011). ">NeoSAMBA</a>). </p> </section> <h3 class="title" id="CD012873-sec-0124">Implications for research</h3> <section id="CD012873-sec-0124"> <p>Further research assessing the role of the sequence in which taxanes are delivered is required to inform more robust discussion and it is expected that trial results from <a href="./references#CD012873-bbs2-0027" title="BinesJ , KestelmanF , SivaSB , SarmentoRMB , SmallIA , RodriguesFR , et al. Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial. Journal of Clinical Oncology2018;36(15):575. NCT012700373 . NeoSAMBA neoadjuvant: does the sequence of anthracycline and taxane matter: before or after?. clinical.tirals.gov/show/NCT01270373 (first received 5 January 2011). ">NeoSAMBA</a> (involving 112 participants) will be published in full‐text in 2019. In particular, reporting of data collected on overall and disease‐free survival is required, so too the quality of life associated with delivering taxane prior to anthracycline compared to anthracycline prior to taxane. Collecting and reporting results by important molecular subgroups (e.g. ER‐positive, triple‐negative breast cancer) and data relating to toxicities are warranted for future trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012873-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012873-sec-0022"></div> <div class="table" id="CD012873-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> neoadjuvant therapy for early breast cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane followed by anthracyclines<br/> <b>Comparison:</b> anthracyclines followed by taxane </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anthracyclines followed by taxane</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane followed by anthracyclines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> (follow‐up: up to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>3‐year risk of death</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.80</b><br/> (0.60 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>947<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<br/> (516 to 729) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free survival</b><br/> (follow‐up: up to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>3‐year risk of recurrence</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.84</b><br/> (0.65 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>828<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>552 per 1000<br/> (463 to 648) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pathological complete response</b> (no invasive cancer in breast or axilla) </p> <p>(follow‐up: up to 5 years for 2 studies; unreported in 2 studies)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/> (0.96 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1280<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/> (219 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neutropenia</b> (grade 3/4) </p> <p>(follow‐up: up to 6 months based on number of chemotherapy cycles)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/> (0.86 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>280<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1000<br/> (218 to 462) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neurotoxicity</b> (grade 3/4) </p> <p>(follow‐up: up to 5 or 6 months based on number of chemotherapy cycles)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b><br/> (0.55 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1108<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/> (25 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment adherence</b> (defined as dose reduction) </p> <p>(follow‐up: up to 6 months based on number of chemotherapy cycles)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.81</b><br/> (0.59 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>280<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>399 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>323 per 1000<br/> (235 to 442) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The baseline risk in the anthracycline followed by taxane group was based on risk estimates provided in <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> (Figure 2D for overall survival; Figure 2B for disease‐free survival).<br/> <sup>b</sup>The number of events did not meet the optimal information size (approximately 120 events in total in one study) and only one study reported follow‐up of five years for overall survival. Therefore, we downgraded by one level for both imprecision and indirectness.<br/> <sup>c</sup>The optimal information size was not met (as per GRADE guidance; <a href="./references#CD012873-bbs2-0041" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64:1283‐93. ">Guyatt 2011</a>). Therefore, we downgraded by one level for imprecision only.<br/> <sup>d</sup>We did not downgrade for imprecision as the optimal information size was met.<br/> <sup>e</sup>The confidence intervals were very wide, indicating no effect and appreciable benefit and harm with taxanes first. Therefore, we downgraded by one level for imprecision.<br/> <sup>f</sup>The confidence intervals were very wide and the impact of unblinding on the assessment of neurotoxicity was unclear. Therefore we downgraded by one level for imprecision and one level for risk of bias.<br/> <sup>g</sup>The optimal information size was not met (as per GRADE guidance; <a href="./references#CD012873-bbs2-0041" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64:1283‐93. ">Guyatt 2011</a>), and the impact of unblinding on treatment adherence was unclear. Therefore, we downgraded by one level only for imprecision and risk of bias. We did not think that risk of bias was very serious due to the design of the studies whereby participants received both treatment drugs but in a different order; therefore, we deducted 0.5 levels for risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012873-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adjuvant therapy for early breast cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane followed by anthracyclines<br/> <b>Comparison:</b> anthracyclines followed by taxane </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anthracyclines followed by taxane</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane followed by anthracyclines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neutropenia (grade 3/4)</b> </p> <p>(follow‐up: up to 3.5 or 4.5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.6</b>2<br/> (0.40 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>279<br/> (4 RCTs, 5 treatment comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>High</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000<br/> (102 to 248) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neurotoxicity (grade 3/4)</b> </p> <p>(follow‐up: up to 4 or 4.5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b><br/> (0.25 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (16 to 156) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment adherence</b> (defined as dose delay) </p> <p>(follow‐up: up to 3.5 or 4.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b><br/> (0.52 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238<br/> (3 RCTs, 4 treatment comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/> (173 to 373) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(follow‐up: up to 4 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported quality of life data using the FACT‐B version 4 questionnaire (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Scores were similar in both groups for a subset of 20 participants who were assessed before, during and after treatment. Numerical or further details were not provided in the trial publication. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade the certainty of the evidence. A lack of blinding was judged to be unlikely to influence physician assessment of grade 3/4 neutropenia (blood tests) and there was no heterogeneity detected across studies.<br/> <sup>b</sup>The confidence intervals were very wide and the impact of unblinding on the assessment of neurotoxicity was unclear. Therefore, we downgraded by one level for imprecision and one level for risk of bias.<br/> <sup>c</sup>The study was open‐label with no independent assessment of this outcome. We did not think that the risk of bias was overly serious due to the design of the study where participants received both treatment drugs but in a different order. The confidence intervals were wide and the optimal information size was not meet. Therefore, we downgraded by one level for both imprecision and risk of bias.<br/> <sup>d</sup>Information for this outcome derived from a very small sample size (from one study). Therefore, we downgraded by one level due to imprecision. We did not downgrade for risk of bias despite this being an open‐label study. This is because all participants received the same treatment though in a different order and this was unlikely to influence participant‐reported responses. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012873-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-sec-0144">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012873-sec-0023"></div> <section id="CD012873-sec-0024"> <h3 class="title" id="CD012873-sec-0024">Description of the condition</h3> <p>Breast cancer is the most common malignancy and the second leading cause of cancer‐related mortality among women worldwide, and thus represents a significant healthcare burden (<a href="./references#CD012873-bbs2-0039" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer2015;136(5):E359‐86. ">Ferlay 2015</a>). Over the past few decades there have been substantial improvements in survival for women with early breast cancer following the introduction of adjuvant (after surgery) and neoadjuvant (before surgery) chemotherapy, endocrine therapy and human epidermal growth factor receptor 2 (HER2)‐directed therapy (<a href="./references#CD012873-bbs2-0034" title="CossettiRJD , TyldesleySK , SpeersCH , ZhengY , GelmonKA . Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. Journal of Clinical Oncology2015;33(1):65‐73. ">Cossetti 2015</a>). </p> </section> <section id="CD012873-sec-0025"> <h3 class="title" id="CD012873-sec-0025">Description of the intervention</h3> <p>Anthracyclines and taxanes are active classes of chemotherapeutic agents used in the adjuvant and neoadjuvant treatment of women with early breast cancer. </p> <p>Anthracyclines (e.g. doxorubicin, epirubicin, liposomal doxorubicin) exert their effect by complexing with DNA and topoisomerase II to induce apoptosis (i.e. cell death) and inhibit DNA and ribonucleic acid (RNA) synthesis. Potential toxicities of anthracyclines include cardiotoxicity, myelosuppression (that results in a reduced number of blood cells) and secondary malignancies (predominantly types of haematological cancer). </p> <p>Taxanes (e.g. docetaxel, paclitaxel, nab‐paclitaxel) exert their effect by stabilising microtubules (fibrous shafts that assist chromosomes to divide), thereby inhibiting cell division and cell function. Potential toxicities of taxanes include neuropathy (i.e. tingling in the hands and feet), myelosuppression and myalgia (muscle pain). </p> <p>At present, standard clinical practice for women with early breast cancer is to administer a regimen of anthracycline‐based chemotherapy followed by a taxane. The reason for this established sequence appears to be historical rather than linked to outcomes. Anthracyclines were developed first and the benefit of anthracycline chemotherapy for early breast cancer was established prior to that of taxanes (<a href="./references#CD012873-bbs2-0044" title="JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">Jones 2006</a>; <a href="./references#CD012873-bbs2-0045" title="LevineMN , BramwellVH , PritchardKI , NorrisBD , ShepherdLE , Abu‐ZahraH , et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node‐positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology1998;16(8):2651‐8. ">Levine 1998</a>). However, one reason to assess the optimal sequence of anthracyclines and taxanes is the finding that outcomes were better when taxanes were given first, in one large retrospective analysis involving approximately 1600 women with breast cancer who received paclitaxel and anthracycline as adjuvant therapy (<a href="./references#CD012873-bbs2-0031" title="AlvarezRH , BianchiniG , HsuL , CristofanilliM , EstevaFJ , PusztaiL , et al. Clinical outcome of two sequences of administering paclitaxel (P) and anthracyclines (A) as primary systemic therapy (PST) and adjuvant chemotherapy (ACT) in breast cancer (BC) patients: a retrospective analysis from the M.D. Anderson Cancer Centre. Cancer Research2010;70(24 Suppl):384s (abstract P5‐10‐02). ">Alvarez 2010</a>). </p> </section> <section id="CD012873-sec-0026"> <h3 class="title" id="CD012873-sec-0026">How the intervention might work</h3> <p>It is unknown whether the order in which taxanes and anthracyclines are administered results in significantly different outcomes for women with early breast cancer. It remains to be determined if the administration of taxanes first leads to better, worse or no difference in treatment outcomes. The effect may also differ depending on the receptor status of the tumour. </p> </section> <section id="CD012873-sec-0027"> <h3 class="title" id="CD012873-sec-0027">Why it is important to do this review</h3> <p>The aim of this review was to assess whether the sequence in which anthracyclines and taxanes are administered, as adjuvant or neoadjuvant chemotherapy, affects outcomes for women with early breast cancer. The results of this review could potentially guide the management of chemotherapy sequencing for women with early breast cancer requiring adjuvant or neoadjuvant chemotherapy. A previous systematic review examined this important topic, but since it was published further trials have been conducted (<a href="./references#CD012873-bbs2-0032" title="BinesJ , EarlH , BuzaidAC , SaadED . Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Annals of Oncology2014;25(6):1079‐85. ">Bines 2014</a>). This Cochrane Review complements the review by <a href="./references#CD012873-bbs2-0032" title="BinesJ , EarlH , BuzaidAC , SaadED . Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Annals of Oncology2014;25(6):1079‐85. ">Bines 2014</a> by adding more recent trial results and critically appraising the included studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012873-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-sec-0149">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012873-sec-0028"></div> <p>To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012873-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-sec-0150">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012873-sec-0029"></div> <section id="CD012873-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012873-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCT) that examined the sequence of administration of anthracyclines and taxanes for people with early breast cancer receiving adjuvant or neoadjuvant chemotherapy. </p> </section> <section id="CD012873-sec-0032"> <h4 class="title">Types of participants</h4> <p>Aged 18 years or older, with early breast cancer suitable for adjuvant or neoadjuvant chemotherapy. </p> </section> <section id="CD012873-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD012873-sec-0034"> <h5 class="title">Intervention</h5> <p>Taxane (docetaxel, paclitaxel or nab‐paclitaxel) chemotherapy administered before an anthracycline‐based chemotherapy. The same regimen of drugs were administered as the comparator arm in reverse sequence. We included studies in which concurrent interventions with any other non‐anthracycline‐based chemotherapy, granulocyte colony stimulating factor or trastuzumab were administered. We excluded studies in which concurrent interventions with radiotherapy or endocrine therapy were administered. Interventions could include: </p> <p> <ul id="CD012873-list-0001"> <li> <p>docetaxel delivered intravenously at any dose weekly, every 14 days or every 21 days for three or four cycles; </p> </li> <li> <p>paclitaxel delivered intravenously at any dose weekly for 12 weeks, every 14 days or 21 days for three or four cycles; </p> </li> <li> <p>nab‐paclitaxel delivered intravenously at any dose weekly or every 21 days for three or four cycles. </p> </li> </ul> </p> </section> <section id="CD012873-sec-0035"> <h5 class="title">Comparator</h5> <p>Anthracycline (doxorubicin, epirubicin or liposomal doxorubicin)‐based chemotherapy administered before taxane chemotherapy. The same regimen of drugs was administered as in the intervention arm but in reverse sequence. We included studies in which concurrent interventions with any non‐taxane chemotherapy or granulocyte colony stimulating factor or trastuzumab were administered. We excluded studies in which concurrent interventions with radiotherapy or endocrine therapy were administered. Comparisons could include: </p> <p> <ul id="CD012873-list-0002"> <li> <p>doxorubicin delivered intravenously at any dose every 14 days or every 21 days for three or four cycles; </p> </li> <li> <p>epirubicin delivered intravenously at any dose every 14 days or every 21 days for three or four cycles; </p> </li> <li> <p>liposomal doxorubicin delivered at any dose or frequency for three or four cycles.</p> </li> </ul> </p> </section> </section> <section id="CD012873-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD012873-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD012873-sec-0038"> <h6 class="title">Neoadjuvant and adjuvant setting</h6> <p> <ul id="CD012873-list-0003"> <li> <p>Overall survival, defined as the time from randomisation/study entry until death from any cause. </p> </li> </ul> </p> </section> </section> <section id="CD012873-sec-0039"> <h5 class="title">Secondary outcomes</h5> <section id="CD012873-sec-0040"> <h6 class="title">Neoadjuvant setting</h6> <p> <ul id="CD012873-list-0004"> <li> <p>Disease‐free survival, defined as time from surgery to first recurrence of breast cancer at any site, development of new ipsilateral (same breast as previous breast cancer) or contralateral (different breast to previous breast cancer) breast cancer or second non‐breast malignant disease with the exception of basal cell or squamous cell carcinoma of the skin, haematological cancers or carcinoma in situ of the cervix. </p> </li> <li> <p>Pathological complete response (pCR), defined as no invasive carcinoma in the breast or axillary lymph nodes (ypT0/isypN0 (TNM staging; <a href="./references#CD012873-bbs2-0030" title="American Joint Committee on Cancer. Breast. In: EdgeSB , ByrdDR , ComptonCC , FritzAG , GreeneFL , TrottiA editor(s). AJCC Cancer Staging Manual. 7th Edition. New York (NY): Springer, 2010:347‐69. ">AJCC 2010</a>)) after neoadjuvant therapy. </p> </li> <li> <p>Standardised Residual Cancer Burden score (RCB; <a href="./references#CD012873-bbs2-0047" title="MD Anderson Cancer Center. Residual Cancer Burden calculator and associated documents (guide for measuring cancer cellularity, examples of gross &amp; microscopic evaluation, pathology protocol for macroscopic and microscopic assessment of RCB). www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3 (accessed 12 April 2017). ">MD Anderson Cancer Center</a>). </p> </li> <li> <p>Degree of response after neoadjuvant therapy:</p> </li> </ul> <ul class="plain" id="CD012873-list-0005"> <li> <ul id="CD012873-list-0006"> <li> <p>no invasive or in situ carcinoma in the breast or axillary lymph nodes (ypT0ypN0);</p> </li> <li> <p>no invasive carcinoma in breast (ypT0/isypN0/+);</p> </li> <li> <p>no invasive carcinoma in axillary lymph nodes (ypN0).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD012873-sec-0041"> <h6 class="title">Adjuvant setting</h6> <p> <ul id="CD012873-list-0007"> <li> <p>Disease‐free survival, defined as time from randomisation to first recurrence of breast cancer at any site, development of new ipsilateral or contralateral breast cancer or second non‐breast malignant disease with the exception of basal cell or squamous cell carcinoma of the skin, haematological cancers or carcinoma in situ of the cervix. </p> </li> </ul> </p> </section> <section id="CD012873-sec-0042"> <h6 class="title">Neoadjuvant and adjuvant setting</h6> <p> <ul id="CD012873-list-0008"> <li> <p>Adverse events classified according to the World Health Organization (WHO) or National Cancer Institute Common Terminology Criteria for Adverse Events (<a href="./references#CD012873-bbs2-0049" title="U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.011. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf (accessed 07 November 2017). ">NCI‐CTCAE</a>): </p> </li> </ul> <ul class="plain" id="CD012873-list-0009"> <li> <ul id="CD012873-list-0010"> <li> <p>febrile neutropenia;</p> </li> <li> <p>neutropenia;</p> </li> <li> <p>cardiac toxicity;</p> </li> <li> <p>pulmonary toxicity;</p> </li> <li> <p>neurotoxicity;</p> </li> <li> <p>haematological malignancy;</p> </li> <li> <p>treatment‐related death.</p> </li> </ul> </li> </ul> <ul id="CD012873-list-0011"> <li> <p>Treatment adherence, defined as delay in treatment or dose reductions, or both, or early cessation of treatment. </p> </li> <li> <p>Quality of life measured using a validated instrument.</p> </li> </ul> </p> </section> <section id="CD012873-sec-0043"> <h6 class="title">Main outcomes in 'Summary of findings' table for summarising the evidence</h6> <p>The following outcomes were included in a 'Summary of findings' table using the GRADE approach (<a href="https://archie.cochrane.org/sections/documents/view?version=z1610100622258916041276713146289%26format=REVMAN#REF-Sch_x00fc_nemann-2011" target="_blank">Schünemann 2011</a>). </p> <p> <ul id="CD012873-list-0012"> <li> <p>Overall survival (mortality).</p> </li> <li> <p>Disease‐free survival (recurrence).</p> </li> <li> <p>pCR for neoadjuvant setting.</p> </li> <li> <p>Treatment adherence.</p> </li> <li> <p>Adverse events including grade 3/4 neutropenia and neurotoxicity.</p> </li> <li> <p>Quality of life.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012873-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012873-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 1 February 2018.</p> <p> <ul id="CD012873-list-0013"> <li> <p>The Cochrane Breast Cancer's Specialised Register. Details of the search strategies used by the Cochrane Breast Cancer Group (CBCG) for the identification of studies and the procedure used to code references are outlined on the Group's website (<a href="http://breastcancer.cochrane.org/sites/breastcancer.cochrane.org/files/public/uploads/specialised_register_details.pdf" target="_blank">Cochrane Breast Cancer Group’s Specialised Register</a>). We extracted and considered for inclusion in the review trials with the key words "breast neoplasm; breast cancer; breast carcinoma; breast adenocarcinoma; breast tumour/tumor; adjuvant; neoadjuvant; anthracycline; taxane; chemotherapy; docetaxel; paclitaxel; nab‐paclitaxel; cabazitaxel; doxorubicin; epirubicin; daunorubicin; idarubicin and valrubicin". </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 1, 2018; in the Cochrane Library; <a href="./appendices#CD012873-sec-0128">Appendix 1</a>). </p> </li> <li> <p>MEDLINE OvidSP (top up search to complement CBCG's Specialised Register; <a href="./appendices#CD012873-sec-0129">Appendix 2</a>). </p> </li> <li> <p>Embase OvidSP (from 1974; <a href="./appendices#CD012873-sec-0130">Appendix 3</a>). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) search portal for all prospectively registered and ongoing trials (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">apps.who.int/trialsearch/Default.aspx</a>; <a href="./appendices#CD012873-sec-0131">Appendix 4</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>; <a href="./appendices#CD012873-sec-0132">Appendix 5</a>). </p> </li> </ul> </p> </section> <section id="CD012873-sec-0046"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD012873-list-0014"> <li> <p>Bibliographic searching.</p> </li> </ul> </p> <p>We tried to identify further studies from the reference lists of identified relevant trials or reviews. We obtained a copy of the full article for each reference reporting a potentially eligible trial. Where this was not possible, we contacted authors to obtain additional information (as outlined in the 'Notes' section in the <a href="./references#CD012873-sec-0140" title="">Characteristics of included studies</a> table). </p> <p> <ul id="CD012873-list-0015"> <li> <p>Searching conference proceedings.</p> </li> </ul> </p> <p>We searched the following conference proceedings in Embase (via OvidSP) from 2006 to 1 February 2018 to identify relevant abstracts: </p> <p> <ul id="CD012873-list-0016"> <li> <p>American Society of Clinical Oncology Annual Scientific Meeting;</p> </li> <li> <p>European Society for Medical Oncology Annual Scientific Meeting;</p> </li> <li> <p>San Antonio Breast Cancer Symposium;</p> </li> <li> <p>American Society of Clinical Oncology Breast Cancer Symposium;</p> </li> <li> <p>European Breast Cancer Conference.</p> </li> </ul> </p> </section> </section> <section id="CD012873-sec-0047"> <h3 class="title" id="CD012873-sec-0047">Data collection and analysis</h3> <section id="CD012873-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We merged the search results using reference management software (e.g. <a href="./references#CD012873-bbs2-0038" title="Thomson Reuters. Endnote X7. Thomson Reuters, 2014. ">Endnote</a>) and uploaded the records into Covidence (<a href="./references#CD012873-bbs2-0035" title="Covidence systematic review software. Veritas Health Innovation, Melbourne, Available at www.covidence.org. ">Covidence</a>). Two review authors (MZ and AG) independently screened titles and abstracts, and assessed full‐text articles for potentially relevant studies for inclusion. We resolved any disagreement about the eligibility of a study by discussion and, if required, by consulting a third review author (NW). We recorded our reasons for the exclusion of any potentially relevant studies in the <a href="./references#CD012873-sec-0141" title="">Characteristics of excluded studies</a> table. We imposed no language restrictions. If required for future review updates, we will obtain translations of relevant studies. We recorded the selection process in a PRISMA flow diagram. </p> </section> <section id="CD012873-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MZ and MW) independently extracted data using standard extraction forms tested and refined for this review. We collected the following information: study design, participants, setting, interventions, follow‐up, sources of funding, notable conflicts of interest of trial authors and outcomes. </p> <p>We extracted at least the following items.</p> <p> <ul id="CD012873-list-0017"> <li> <p>General information: title, authors, contact details, location, publication status, language, year of publication, source of funding. </p> </li> <li> <p>Trial characteristics: study design, length of follow‐up.</p> </li> <li> <p>Participants: inclusion and exclusion criteria, sample size, baseline characteristics and similarity at baseline, neoadjuvant/adjuvant setting, hormone receptor status, HER2 in‐situ hybridisation status, withdrawals, losses to follow‐up. </p> </li> <li> <p>Intervention and comparator: drug, dose, timing and number of cycles, dose reductions, dose omissions. </p> </li> <li> <p>Adverse events and toxicities.</p> </li> <li> <p>Outcomes: hazard ratios (HR) and 95% confidence intervals (CI), log rank Chi² statistic, P values from log‐rank test, number of events. </p> </li> </ul> </p> <p>We resolved any disagreement regarding the extraction of quantitative data by discussion and, if required, by consulting a third review author (NW, AG or DO'C). For studies with more than one publication, we collated data from each publication into a single data collection form and considered the final or updated version of each study the primary reference. </p> </section> <section id="CD012873-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MZ and MW) independently assessed the risk of bias for each study using Cochrane's 'Risk of bias' assessment tool, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8.5; <a href="./references#CD012873-bbs2-0043" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreements by discussion and, if needed, by consulting a third author (AG, NW or DO'C). We assessed the following sources of bias: </p> <p> <ul id="CD012873-list-0018"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, personnel;</p> </li> <li> <p>blinding of outcome assessment for outcomes other than overall survival;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We described the 'Risk of bias' assessments in a 'Risk of bias' table (see <a href="./references#CD012873-sec-0140" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD012873-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (i.e. a variable with only two outcomes such as yes or no) – treatment adherence (i.e. dose delays, dose reductions, one‐dose reduction, did not receive planned number of cycles), pCR and adverse events – we reported the treatment effect as a risk ratio (RR) and 95% CI. We planned to report the number needed to treat for an additional beneficial outcome if there was a significant difference in pCR. RRs less than 1.0 favour the administration of taxanes first for adverse outcomes (i.e. lack of treatment adherence, adverse events) or favour administration of anthracyclines first for beneficial outcomes (i.e. pCR). The reverse is the case for RRs greater than 1.0. </p> <p>In review updates, for continuous outcomes (where measurement is continuous on a numerical scale) – quality of life – we will report the treatment effect as a standardised mean difference and 95% CI as quality of life is expected to be measured using different scales. If all studies use the same scale, we will report the mean difference. In the current review, only one study measured quality of life but did not report any numerical data. There was a second continuous outcome reported, mean dose intensity for treatment adherence, but a measure of variation was not reported for this outcome. Therefore, the data could not be pooled in a meta‐analysis and are presented in a separate table for completeness (see <a href="#CD012873-tbl-0003">Table 1</a> and <a href="#CD012873-tbl-0004">Table 2</a>). </p> <div class="table" id="CD012873-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment adherence measures for neoadjuvant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence measure reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane followed by anthracycline (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline followed by taxane (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who received ≥ 90% of planned dose of paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121/142 (85.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124/138 (89.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who received ≥ 90% of planned dose of FEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123/142 (86.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103/138 (74.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received ≥ 20 weeks of the planned 24 weeks of trastuzumab<sup>a</sup> or ≥ 10 weeks of planned 12 weeks of trastuzumab<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127/142 (89.4%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126/138 (91.3%)<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose reductions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/142 (32.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/138 (39.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinued due to intolerance (severe toxic effects)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/142 (6.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/138 (6.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose intensity<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane: 97.%</p> <p>Doxorubicin: 94.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin: 95.2%</p> <p>Taxane: 89.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cycle delivered dose intensity<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of cycles with dose reductions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane → epirubicin: 3%<br/> Taxane + gemcitabine → epirubicin: 5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin → taxane: 6%<br/> Epirubicin + gemcitabine → taxane: 9% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of cycles with dose delays</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane → epirubicin: 15%<br/> Taxane + gemcitabine → epirubicin: 15% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin → taxane: 15%<br/> Epirubicin + gemcitabine → taxane: 16% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEC: fluorouracil, epirubicin and cyclophosphamide; n: number of participants with delay or dose reduction, etc; N: denominator; NR: not reported. </p> <p><sup>a</sup>≥ 20 weeks of the planned 24 weeks of trastuzumab.<br/> <sup>b</sup>≥ 10 weeks of planned 12 weeks of trastuzumab.<br/> <sup>c</sup>Calculated as percentage of planned dose intensity delivered<br/> <sup>d</sup>Calculated as mean of the individual drug delivered dose intensities planned for that cycle; course drug delivered dose as mean of course drug delivered doses over planned number of cycles, per participant. </p> </div> </div> <div class="table" id="CD012873-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dose intensity data for adjuvant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term used to represent dose intensity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane followed by anthracycline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline followed by taxane </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean relative dose intensity<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 95.2%</p> <p>FEC: 98.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 94.2%</p> <p>FEC: 97.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median relative dose intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 96% (range: 25–104)</p> <p>Epirubicin: 96% (range: 0–102)</p> <p>Cyclophosphamide: 95% (range: 0–102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 81% (range: 0–102)</p> <p>Epirubicin: 97% (range: 66–102)</p> <p>Cyclophosphamide: 97% (range: 61–102)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean relative dose intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 96%</p> <p>Doxorubicin: 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 82%</p> <p>Doxorubicin: 96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean dose intensity<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 99%</p> <p>FEC: 97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 97%</p> <p>FEC: 97%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a> (dose‐dense) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean dose intensity<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 111%</p> <p>FEC: 143%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 108%</p> <p>FEC: 146%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEC: fluorouracil, epirubicin, cyclophosphamide.</p> <p><sup>a</sup>Data used based on the reporting of findings in the abstract and Table 2 in the trial publication. The docetaxel and FEC percentages were switched in the text in the Results section. Therefore, the consistency of results presented in Table 2 and abstract were considered to be the most accurate reflection of the results. </p> <p><sup>b</sup>Defined as the dose intensity achieved in intervention or comparator arm for a participant who received all intended doses with no cycle delay or dose reduction. </p> </div> </div> <p>For time‐to‐event outcomes – disease‐free survival and overall survival – we reported the treatment effect as a HR and 95% CI. For those studies that reported overall survival or disease‐free survival data, we extracted the HR and associated variances directly from the trial publications. In review updates, if this is not possible, we will obtain the data indirectly, using methods described by <a href="./references#CD012873-bbs2-0050" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> or <a href="./references#CD012873-bbs2-0053" title="TierneyJ , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>. We will record the use of indirect methods in the Notes section of the <a href="./references#CD012873-sec-0140" title="">Characteristics of included studies</a> table. We reported the ratios of treatment effects for response so that HRs less than 1.0 favoured the administration of taxanes first and HRs greater than 1.0 favoured the administration of anthracyclines first. </p> </section> <section id="CD012873-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>In the neoadjuvant setting, <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> was a four‐arm study that randomised women to anthracycline then paclitaxel or reverse order with or without gemcitabine. For the purpose of this review, we combined the two intervention arms (taxane followed by anthracycline with or without gemcitabine) and the two comparison arms (anthracycline followed by taxane with or without gemcitabine). </p> <p>In the adjuvant setting, <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a> was a three‐arm study and we only included the data relating to treatments with both a taxane and anthracycline. The Wildiers study was a four‐arm study that randomised women to either conventional chemotherapy (taxane followed by anthracycline or in reverse order) or dose‐dense treatment (taxane followed by anthracycline or in reverse order). We used data from all four treatments arms and split them into two treatment comparisons: <a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a> and <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>. </p> </section> <section id="CD012873-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of some included studies in writing to request missing data (e.g. overall survival, disease‐free survival and relative dose intensity outcome data) (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). </p> </section> <section id="CD012873-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the degree of heterogeneity by visual inspection of forest plots, the I² statistic (<a href="./references#CD012873-bbs2-0042" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), and the Chi² test for heterogeneity (<a href="./references#CD012873-bbs2-0033" title="CochranWG . The combination of estimates from different experiments. Biometrics1954;10(1):101‐29. ">Cochran 1954</a>). We considered there to be substantial statistical heterogeneity if the I² statistic was greater than 50% and the P value was less than 0.10 for the Chi² test for heterogeneity. For this initial review, as the expected number of included trials was small and, therefore, we did not expect significant heterogeneity, we used the fixed‐effect model. In review updates, we plan to use the random‐effects model (see <a href="#CD012873-sec-0056">Data synthesis</a>) for pooling estimates across trials unless the results are affected by the inclusion of small studies. If this occurs, then we will also use the fixed‐effect model and compare the results. </p> </section> <section id="CD012873-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>As the review included fewer than 10 studies, we did not formally assess publication bias using funnel plots. If additional studies are available in review updates, we will assess publication or other bias by visual examination of funnel plot symmetry provided there are at least 10 studies in the meta‐analysis (<a href="./references#CD012873-bbs2-0043" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Where possible, we will review the protocols of included studies to assess outcome reporting bias. </p> </section> <section id="CD012873-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We pooled data using the fixed‐effect model as sufficiently similar (in terms of population and intervention) studies were available to provide meaningful results in the neoadjuvant and adjuvant settings. We performed all analyses using Review Manager 5 software (<a href="./references#CD012873-bbs2-0051" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>For dichotomous outcomes, we used the fixed‐effect method (Mantel‐Haenszel; <a href="./references#CD012873-bbs2-0046" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). In review updates, we will use the random‐effects method (<a href="./references#CD012873-bbs2-0037" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). </p> <p>Data could not be pooled for continuous outcomes in this review. However, in review updates, for continuous outcomes, we will use the random‐effects with inverse variance method (<a href="./references#CD012873-bbs2-0036" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>For time‐to‐event outcomes, we used the fixed‐effect with inverse variance method. In review updates, we will use the random‐effects (DerSimonian and Laird with inverse‐variance) method. </p> <p>In review updates, if we are concerned about the effect of small studies on the random‐effects meta‐analysis, we will compare the fixed‐effect and random‐effects estimates. If results from the fixed‐effect and random‐effects analysis are different, we will perform sensitivity analyses to consider restricting the meta‐analysis to include the larger studies only. </p> <section id="CD012873-sec-0057"> <h5 class="title">'Summary of findings' table</h5> <p>Two review authors (MZ and MW) used the GRADE approach to assess the certainty of the evidence for the following outcomes: overall survival (event: risk of death), disease‐free survival (event: risk of recurrence), pCR, treatment adherence, adverse events and quality of life. We used <a href="./references#CD012873-bbs2-0040" title="GRADEproGDT. McMaster University (developed by Evidence Prime), Hamilton (ON). Available at gradepro.org. ">GRADEpro GDT</a> software to develop the 'Summary of findings' tables and followed GRADE guidance (<a href="./references#CD012873-bbs2-0052" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlaziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). </p> <p>To calculate the absolute risk for the control group for time‐to‐event outcomes, we derived the event rate at a specific time point (three‐year risk for both overall survival and disease‐free survival) from the Kaplan‐Meier curve in the <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> study; only the neoadjuvant studies reported data for overall survival and disease‐free survival. We entered the event rate at three years and the pooled HR into <a href="./references#CD012873-bbs2-0040" title="GRADEproGDT. McMaster University (developed by Evidence Prime), Hamilton (ON). Available at gradepro.org. ">GRADEpro GDT</a> and estimated the corresponding absolute risk for the intervention group at three years by the <a href="./references#CD012873-bbs2-0040" title="GRADEproGDT. McMaster University (developed by Evidence Prime), Hamilton (ON). Available at gradepro.org. ">GRADEpro GDT</a> software. </p> </section> </section> <section id="CD012873-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We presented data separately for participants receiving neoadjuvant and adjuvant chemotherapy. We presented data from one or two trials separately for the following prespecified patient subgroups: </p> <p> <ul id="CD012873-list-0019"> <li> <p>people with positive versus negative HER2 status;</p> </li> <li> <p>people with positive, negative or triple negative hormone receptor status.</p> </li> </ul> </p> <p>In review updates, we will conduct tests for interaction to determine whether the sequence in which anthracyclines and taxanes are administered has a significantly different effect in subgroups. </p> </section> <section id="CD012873-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>Due to the limited data available, the proposed sensitivity analysis was not undertaken. In review updates, we plan to perform the following sensitivity analysis: </p> <p> <ul id="CD012873-list-0020"> <li> <p>risk of bias: low versus high/unclear risk of bias. We will assign an overall unclear/high risk of bias to studies in which we have judged at least four of the seven domains to have unclear/high risk of bias. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012873-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012873-sec-0060"></div> <section id="CD012873-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD012873-sec-0062"> <h4 class="title">Results of the search</h4> <p>We outlined the search process in the PRISMA flow diagram (<a href="#CD012873-fig-0001">Figure 1</a>; <a href="./references#CD012873-bbs2-0048" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. ">Moher 2009</a>). We identified 4564 records through searching CBCG's Specialised Register, CENTRAL, MEDLINE and Embase (that included American Society of Clinical Oncology and San Antonio Breast Cancer Symposium conference proceedings), and an additional 914 records from the WHO ICTRP and ClinicalTrials.gov. After removal of duplicate records, from 5478 unique records we excluded 5444 records based on review of the titles and abstracts retrieved. We retrieved 34 full‐text articles, abstracts or clinical trial records and on review excluded 15 records that did not meet the selection criteria (<a href="./references#CD012873-sec-0141" title="">Characteristics of excluded studies</a> table). The predominant reason for exclusion was that studies did not compare the reverse order of taxanes and anthracyclines in two treatment arms. There was one additional record relating to an abstract from a cancer conference and we wait for the results to be published. This record has been added to the <a href="./references#CD012873-sec-0142" title="">Characteristics of studies awaiting classification</a> table. The remaining 20 records related to: </p> <div class="figure" id="CD012873-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012873-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p> <ul id="CD012873-list-0021"> <li> <p>five included studies (eight records) referring to five treatment comparisons in the neoadjuvant setting (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>); </p> </li> <li> <p>four included studies (six records) referring to five treatment comparisons in the adjuvant setting (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)); </p> </li> <li> <p>three studies awaiting classification (five records: <a href="./references#CD012873-bbs2-0026" title="MasudaN , SatoN , HigakiK , KashiwabaM , MatsunamiN , TakanoT , et al. A prospective multicenter randomized phase II neo‐adjuvant study of 5‐fluorouracil epirubicin and cyclophosphamide (FEC) followed by docetaxel cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone in patients (pts) with operable HER2 positive breast cancer: JBCRG‐10 study. San Antonio Breast Cancer Symposium; 2012 Dec 4‐8; San Antonio (TX). 2012:P1‐14‐01. ">Masuda 2012</a>; <a href="./references#CD012873-bbs2-0027" title="BinesJ , KestelmanF , SivaSB , SarmentoRMB , SmallIA , RodriguesFR , et al. Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial. Journal of Clinical Oncology2018;36(15):575. NCT012700373 . NeoSAMBA neoadjuvant: does the sequence of anthracycline and taxane matter: before or after?. clinical.tirals.gov/show/NCT01270373 (first received 5 January 2011). ">NeoSAMBA</a>; <a href="./references#CD012873-bbs2-0028" title="CorbenAD , Abi‐RaadR , PopaI , TeoCH , MacklinEA , KoernerFC , et al. Pathologic response and long‐term follow‐up in breast cancer patients treated with neoadjuvant chemotherapy. Archives of Pathology &amp; Laboratory Medicine2013;137:1074‐82. TaghianAG , Abi‐RaadR , AssaadSI , CastyA , AncukiewiczM , YehE , et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. Journal of Clinical Oncology2005;23(9):1951‐61. ">Taghian 2005</a>); and </p> </li> <li> <p>one ongoing study (one record: <a href="./references#CD012873-bbs2-0029" title="UMIN000003283 . A randomized study of docetaxel + cyclophosphamide (TC), 5‐fluorouracil + epirubicin + cyclophosphamide (FEC)‐TC and TC‐FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer JBCRG‐09. https://upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003873&amp;language=J Date first received: 3 March 2010. ">UMIN000003283</a>). </p> </li> </ul> </p> </section> <section id="CD012873-sec-0063"> <h4 class="title">Included studies</h4> <p>See <a href="https://archie.cochrane.org/sections/documents/view?version=z1710270649102759389595139603953%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table. </p> <section id="CD012873-sec-0064"> <h5 class="title">Neoadjuvant studies</h5> <p>The five included studies involved 1415 participants (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). Three studies used paclitaxel (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), and two studies used docetaxel (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>), as taxane chemotherapy. Two studies used single agent doxorubicin (<a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), and three studies used epirubicin as anthracycline chemotherapy (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). Two studies used epirubicin with cyclophosphamide and fluorouracil (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>), and one study used epirubicin and cyclophosphamide (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). One study used paclitaxel every two weeks with or without gemcitabine (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). </p> <p>In terms of the characteristics of trial participants, one study included T1‐3, N0‐3 disease (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>), one study included only participants with tumour size greater than 20 mm (T2) with or without axillary lymph node involvement (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>), and two studies included participants with either tumour size greater than 20 mm (T2) or lymph node involvement (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>). One study included participants with stage IV disease but presented data separately for stage III disease and could be used (<a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). In all studies, the majority of trial participants had axillary lymph node‐positive disease. One study included HER2‐positive participants only (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>), and another study was designed and commenced prior to the introduction of trastuzumab (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). All studies had included participants whose breast cancer was HER2‐positive, hormone receptor‐positive or hormone receptor‐negative and included both premenopausal and postmenopausal women. </p> <p>In relation to the outcomes assessed in the studies, the primary outcome for two of the studies was to identify a marker that correlated with tumour response to chemotherapy (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>). One of these studies also reported overall and disease‐free survival (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>). All studies used different definitions of pCR. Four studies reported on no invasive cancer in the breast or axilla (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). Only one study reported no invasive or in situ carcinoma in the breast or axilla and was included in a separate analysis for pCR (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>). No studies reported on RCB or quality of life outcomes. </p> <p>One study was funded solely by a government grant (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>), and four studies were supported by a government or cancer society grant combined with a research grant from a pharmaceutical company (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). </p> </section> <section id="CD012873-sec-0065"> <h5 class="title">Adjuvant studies</h5> <p>The four included studies involved 280 participants and contributed to five treatment comparisons (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). All studies used docetaxel as taxane chemotherapy. Two studies with three treatment comparisons used epirubicin with cyclophosphamide and fluorouracil (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)), one study used epirubicin with cyclophosphamide (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>), and one study used adriamycin and cyclophosphamide (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Three treatment comparisons included dose‐dense regimens (where at least the same amount of chemotherapy was given over a shorter period of time, i.e. 300 mg/m² in total given in four cycles of fortnightly docetaxel at 75 mg/m² rather than three cycles of three‐weekly docetaxel at 100 mg/m²) (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>). The Wildiers study had two treatment comparisons involving dose dense and conventional regimen (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>). There were two treatment comparisons that compared conventional three‐weekly regimens (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>). </p> <p>For two studies, participants had to have axillary lymph node involvement (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>), and for the other two studies they did not (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). For two studies, HER2‐positive participants were able to participate if they were ineligible for or chose not to participate in adjuvant trastuzumab trials (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). One study did not report the HER2 status of participants (Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). Overall, a small proportion (12%) of the included participants had HER2‐positive disease. </p> <p>In relation to the outcomes assessed in the studies, all studies were primarily investigating toxicity and treatment adherence. One study collected data on overall and disease‐free survival (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). One study reported collecting data on quality of life and made a brief statement of the findings in the Discussion section of the published article (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>); numerical data were not provided. </p> <p>One study provided no information about funding (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>), one study was supported by a government or cancer society grant combined with a research grant from industry (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>), and two studies were supported with grants from a pharmaceutical company (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). </p> </section> </section> <section id="CD012873-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 studies (<a href="https://archie.cochrane.org/sections/documents/view?version=z1710270649102759389595139603953%26format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a> table). The most common reason for exclusion was that they were not evaluating the sequencing of taxanes and anthracyclines (<a href="./references#CD012873-bbs2-0011" title="Akashi‐TanakaS , TaninoY , YamamotoY , NishimiyaH , Yamamoto‐ibusukiM , IwaseH , et al. BRCAness and prognosis of triple‐negative breast cancer patients treated with neoadjuvant chemotherapy. Journal of Clinical Oncology2017;35(15 Suppl 1):e12111. ">Akashi‐Tanaka 2017</a>; <a href="./references#CD012873-bbs2-0013" title="Anonymous . Epirubicin and cyclophosphamide (EC) vs docetaxel (d) followed by EC in adjuvant (ADJ) treatment of node positive (pN1) breast cancer (BC) – a multicenter randomized phase III study. Proceedings of the American Society of Clinical Oncology2001;20(Part 2):22b. ">Anonymous 2001</a>; <a href="./references#CD012873-bbs2-0014" title="BuzdarA , HuntK , SmithT , FrancisD , EwerM , BooserD , et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline‐containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Journal of Clinical Oncology2004;7:520. ">Buzdar 2004</a>; <a href="./references#CD012873-bbs2-0017" title="EarlH . Phase I/II randomized study of neoadjuvant sequential epirubicin and docetaxel in women with poor‐risk early breast cancer. Physician Data Query2003. ">Earl 2003</a>; <a href="./references#CD012873-bbs2-0021" title="SkarlosP , ChristodoulouC , KalogerasKT , EleftherakiAG , BobosM , BatistatouA , et al. Triple‐negative phenotype is of adverse prognostic value in patients treated with dose‐dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemotherapy and Pharmacology2012;69(2):533‐46. ">Skarlos 2012</a>; <a href="./references#CD012873-bbs2-0023" title="ThomasJ , ProvenzanoE , HillerL , DunnJ , BlenkinsopC , GrybowiczL , et al. Central pathology review with two‐stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology2017;30(8):1069‐77. ">Thomas 2017</a>; <a href="./references#CD012873-bbs2-0024" title="WildiersH . A randomized phase II trial exploring feasibility of densification and optimal sequencing of postoperative adjuvant fluorouracil, epirubicin plus cyclophosphamide (FEC) and docetaxel chemotherapy in patients with high risk primary operable breast cancer. Physician Data Query2006. ">Wildiers 2006</a>). The second most common reason was inclusion of the wrong participant population (<a href="./references#CD012873-bbs2-0016" title="CrestaS , GraselliG , MartoniA , LelliG , MansuttiM , CapriG , et al. A randomized phase II study of alternating (AA) vs sequential (SS) vs the combination (CC) of doxorubicin (A) and docetaxel (T) as 1st line CT in MBC PTS. Proceedings of the American Society of Clinical Oncology2001;20(Pt 1):48a. ">Cresta 2001</a>; <a href="./references#CD012873-bbs2-0019" title="FocanC , GraasM , BeauduinM , CanonJ , SalmonJ , JerusalemG , et al. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Anticancer Research2005;25(2b):1211‐7. ">Focan 2005</a>; <a href="./references#CD012873-bbs2-0022" title="NahlehZA , BarlowWE , HayesDF , SchottAF , GralowJR , SikovWM , et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab‐paclitaxel with dose‐dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research and Treatment2016;158(3):485‐95. ">SWOG S0800</a>; <a href="./references#CD012873-bbs2-0025" title="ZoliW , UliviP , TeseiA , FabbriF , RosettiM , MaltoniR , et al. Addition of 5‐fluorouracil to doxorubicin‐paclitaxel sequence increases caspase‐dependent apoptosis in breast cancer cell lines. Breast Cancer Research2005;7(5):R681‐9. ">Zoli 2005</a>). The third most common reason was that they were not RCTs, rather they were either non‐randomised or retrospective studies (<a href="./references#CD012873-bbs2-0015" title="CardosoF , FerreiraFA , CrownJ , DolciS , PaesmansM , RivaA , et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Research2001;21(1b):789‐95. ">Cardoso 2001</a>; <a href="./references#CD012873-bbs2-0018" title="FabianoA , FilhoF , CrownJ , CardosoF , NogaretJM , DuffyK , et al. 3‐Year results of docetaxel‐based sequential and combination regimens in the adjuvant therapy of node‐positive breast cancer: a pilot study. Anticancer Research2002; Vol. 22, issue 4:2471‐6. ">Fabiano 2002</a>). One study used different anthracycline regimens in the comparison arms when sequencing taxane (<a href="./references#CD012873-bbs2-0020" title="GuarneriV , FrassoldatiA , GebbiaV , BisagniG , CavannaL , DonadioM . 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: preliminary cardiac safety data of the phase III multicentric Italian study short‐HER. Cancer Research2010;70(24 Suppl):P5‐12‐05. ">Guarneri 2010</a>), and one study was a meta‐analysis (<a href="./references#CD012873-bbs2-0012" title="AlbainK , AndersonS , ArriagadaR , BarlowW , BerghJ , BlissJ , et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta‐analyses of long‐term outcome among 100 000 women in 123 randomised trials. Lancet2012;379(9814):432‐44. ">Albain 2012</a>). </p> <section id="CD012873-sec-0067"> <h5 class="title">Studies awaiting classification</h5> <p>The <a href="./references#CD012873-bbs2-0026" title="MasudaN , SatoN , HigakiK , KashiwabaM , MatsunamiN , TakanoT , et al. A prospective multicenter randomized phase II neo‐adjuvant study of 5‐fluorouracil epirubicin and cyclophosphamide (FEC) followed by docetaxel cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone in patients (pts) with operable HER2 positive breast cancer: JBCRG‐10 study. San Antonio Breast Cancer Symposium; 2012 Dec 4‐8; San Antonio (TX). 2012:P1‐14‐01. ">Masuda 2012</a> study reported results in an abstract only. The study examined the sequence of treatments for women with HER2‐positive breast cancer in the neoadjuvant setting. There were insufficient details provided in the abstract and we await the complete trial publication. We contacted the trialists in May 2018 and we received no reply. </p> <p>The <a href="./references#CD012873-bbs2-0028" title="CorbenAD , Abi‐RaadR , PopaI , TeoCH , MacklinEA , KoernerFC , et al. Pathologic response and long‐term follow‐up in breast cancer patients treated with neoadjuvant chemotherapy. Archives of Pathology &amp; Laboratory Medicine2013;137:1074‐82. TaghianAG , Abi‐RaadR , AssaadSI , CastyA , AncukiewiczM , YehE , et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. Journal of Clinical Oncology2005;23(9):1951‐61. ">Taghian 2005</a> study was reported in two publications though neither reported pCR (although this was listed in the clinical trials registry record), or overall survival and disease‐free survival for each treatment group. We contacted trialists in August 2018 and they responded that they have not yet analysed the clinical outcome data for each treatment group, though they intend to do so soon. This will be included in a review update. </p> <p>The <a href="./references#CD012873-bbs2-0027" title="BinesJ , KestelmanF , SivaSB , SarmentoRMB , SmallIA , RodriguesFR , et al. Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial. Journal of Clinical Oncology2018;36(15):575. NCT012700373 . NeoSAMBA neoadjuvant: does the sequence of anthracycline and taxane matter: before or after?. clinical.tirals.gov/show/NCT01270373 (first received 5 January 2011). ">NeoSAMBA</a> study was identified through searches of the clinical trial registry databases and after the search date of this review, it was noted that the study reported preliminary results in the form of a conference abstract. We await the full‐text publication of this study in 2019. The study examined the sequence of treatments for women with locally advanced HER2‐negative breast cancer and the primary outcome was pCR and secondary outcomes included disease‐free survival and overall survival. </p> </section> <section id="CD012873-sec-0068"> <h5 class="title">Ongoing studies</h5> <p>We identified one ongoing neoadjuvant study through searches of the WHO ICTRP and ClinicalTrials.gov databases (<a href="./references#CD012873-bbs2-0029" title="UMIN000003283 . A randomized study of docetaxel + cyclophosphamide (TC), 5‐fluorouracil + epirubicin + cyclophosphamide (FEC)‐TC and TC‐FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer JBCRG‐09. https://upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003873&amp;language=J Date first received: 3 March 2010. ">UMIN000003283</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1710270649102759389595139603953%26format=REVMAN#CHARACTERISTICS_OF_ONGOING_STUDIES" target="_blank">Characteristics of ongoing studies</a> table). </p> </section> </section> </section> <section id="CD012873-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD012873-fig-0002">Figure 2</a> shows a summary of the risk of bias judgements of the included studies for each 'Risk of bias' domain. For each risk of bias domain, we combined the judgements for neoadjuvant and adjuvant studies. A summary of risk of bias assessments for each treatment setting is provided at the end of this section. </p> <div class="figure" id="CD012873-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012873-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012873-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD012873-sec-0071"> <h5 class="title">Random sequence generation</h5> <p>The nine studies, relating to 10 treatment comparisons in the neoadjuvant and adjuvant settings, were described as randomised. Eight studies reporting nine treatment comparisons described the method of random sequence generation adequately (i.e. with low risk of bias; <a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). These studies used a biased coin minimisation algorithm, stratified randomisation or minimisation. For one study, there was insufficient information to accurately assess the method of random sequence generation (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>); the study was at unclear risk of bias. </p> </section> <section id="CD012873-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>Four studies, reporting five treatment comparisons, were at low risk of bias for allocation concealment. These studies described central randomisation systems (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). Five studies did not describe methods of allocation concealment or did not provide sufficient detail in the trial publication and were at unclear risk of bias (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). </p> </section> </section> <section id="CD012873-sec-0073"> <h4 class="title">Blinding</h4> <section id="CD012873-sec-0074"> <h5 class="title">Blinding of participants and personnel</h5> <p>Five studies, reporting six treatment comparisons, were described as open label (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)), while four studies provided no information in the trial publication and were likely to have been open label (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). Performance bias was unlikely to be significant given that participants received both drug treatments just in reverse order. Therefore, performance bias was not viewed to be serious and studies were judged at low risk of bias for this domain. </p> </section> <section id="CD012873-sec-0075"> <h5 class="title">Blinding of outcome assessments</h5> <p>We assessed detection bias for each outcome: overall survival, disease‐free survival, pCR (for neoadjuvant studies only), toxicity and treatment adherence (these outcomes were combined because grade of toxicity is entwined with treatment adherence, i.e. a drug dose is reduced or delayed, etc if high‐grade toxicities occur) and, quality of life. </p> <p>The assessment of overall survival and disease‐free survival was perceived not be biased by a lack of blinding. Therefore, the five studies that collected or reported (or both) overall survival (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), and the five studies that collected or reported (or both) on disease‐free survival (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), were at low risk of bias. </p> <p>For pCR, there was a lack of blinding perceived to be unlikely to lead to material bias given that the assessment of pCR by a pathologist is an objective assessment. In one study, two independent assessors determined pCR (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>); in one study, one independent assessor determined pCR (<a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>); while the remaining three studies did not use an independent assessor (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). Overall, all studies were at low risk of bias. </p> <p>For outcome measures that were more likely to be influenced by a lack of blinding, that is, toxicity and treatment adherence, we considered for each study whether outcome assessments were confirmed by independent panels/adjudication committees and how toxicity outcomes were measured (e.g. blood tests). Most studies that assessed one or more of these outcomes had unclear risk of bias as there was no independent clinical review group and the toxicity measure collected (e.g. neuropathy) may have been influenced by the lack of blinding (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). However, one study reporting two treatment comparisons (Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)) reported only two toxicity outcomes relevant to this review – febrile neutropenia and neutropenia. These toxicities were diagnosed using blood tests and so were less likely to be influenced by the lack of blinding; therefore, they were at low risk of bias for this domain. </p> <p>Only one study collected and reported quality of life information (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Participants who knew their treatment allocation completed quality of life questionnaires. However, all participants in the same study received the same treatments though in a different order; therefore, the study was at low risk of bias as lack of blinding was unlikely to influence participant‐reported responses. </p> </section> </section> <section id="CD012873-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>All studies described minimal participant loss during the study and accounted for these losses; therefore, they were at low risk of bias (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). </p> </section> <section id="CD012873-sec-0077"> <h4 class="title">Selective reporting</h4> <p>Seven studies, reporting eight treatment comparisons, had either reported results for those outcomes listed in the methods section of the trial publication (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)) or a trial registration record with the outcomes as included in the methods and results section of the trial publication (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). <a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a> and <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> reported some additional toxicity outcomes, while in two trials, there were some changes to the primary or secondary outcomes with both adding new and important outcomes (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>: pCR; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>: relative dose intensity and quality of life). Overall, we judged these seven studies (eight treatment comparisons) at low risk of bias. <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a> was at high risk of bias for this domain as data related to both overall survival and disease‐free survival were not reported despite the study being completed in 2004. We contacted the authors for data and received no response (as of July 2018). <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> was at high risk of bias due to having reported important outcomes (overall survival and recurrence) but omitted reporting the data separately for each treatment group and, therefore, the data could not be used for the treatment comparisons. </p> </section> <section id="CD012873-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were generally free of other sources of bias.</p> <section id="CD012873-sec-0079"> <h5 class="title">Summary of risk of bias by treatment setting</h5> <section id="CD012873-sec-0080"> <h6 class="title">Neoadjuvant studies</h6> <p>Overall, the risk of bias was low for most domains across the neoadjuvant studies. The two main exceptions related to the lack of, or insufficient details to assess, allocation concealment (in three out of the five studies), and uncertainty in the risk of bias when assessing toxicity/treatment adherence outcomes when studies were unblinded (in all four studies reporting on this outcome). All of the studies collected data on prespecified outcomes. However, one study did not report important efficacy outcome data separately for each treatment group (<a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). </p> </section> <section id="CD012873-sec-0081"> <h6 class="title">Adjuvant studies</h6> <p>Overall, the risk of bias was low for most domains with some concern in risk of bias being noted due to unblinding of outcome assessments for toxicity and treatment adherence. Although all studies reported the prespecified outcomes, one study omitted to report important outcome data that were collected in 2004 (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). We contacted the trial authors in July 2018 and are yet to receive a reply. Therefore, we rated this study at high risk of bias for selective outcome reporting. </p> </section> </section> </section> </section> <section id="CD012873-sec-0082"> <h3 class="title" id="CD012873-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD012873-tbl-0001"><b>Summary of findings for the main comparison</b> Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</a>; <a href="./full#CD012873-tbl-0002"><b>Summary of findings 2</b> Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</a> </p> <section id="CD012873-sec-0083"> <h4 class="title">Neoadjuvant setting</h4> <p>Five included studies (eight records) referred to five treatment comparisons in the neoadjuvant setting (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). See: <a href="./full#CD012873-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012873-sec-0084"> <h5 class="title">Overall survival</h5> <p>Four studies collected data on overall survival (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>); however, data from one study are yet to be published (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>), and one study did not report data separately for each treatment group (<a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). Based on data from two studies (947 participants), administering taxanes first probably resulted in little to no difference in overall survival compared to administering anthracyclines first (HR 0.80, 95% CI 0.60 to 1.08; moderate‐certainty evidence; <a href="./references#CD012873-fig-0006" title="">Analysis 1.1</a>; <a href="#CD012873-fig-0003">Figure 3</a>). Only one study provided an indication of the number of deaths with <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> reporting that more than 120 participants had died over the three‐year median follow‐up period. </p> <div class="figure" id="CD012873-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.1 Overall survival." data-id="CD012873-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.1 Overall survival.</p> </div> </div> </div> </section> <section id="CD012873-sec-0085"> <h5 class="title">Disease‐free survival</h5> <p>Three studies involving 1132 participants collected data on disease‐free survival (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), but only one study reported data (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). <a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a> collected data but the data for this type of outcome are not yet mature to present and <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> did not report data separately for each treatment group. Based on one study, administering taxanes first probably resulted in little to no difference in disease‐free survival compared to administering anthracyclines first (HR 0.84, 95% CI 0.65 to 1.09; 828 participants; moderate‐certainty evidence; <a href="./references#CD012873-fig-0007" title="">Analysis 1.2</a>; <a href="#CD012873-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012873-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.2 Disease‐free survival." data-id="CD012873-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.2 Disease‐free survival.</p> </div> </div> </div> </section> <section id="CD012873-sec-0086"> <h5 class="title">Pathological complete response</h5> <p>All five studies provided some data relating to pathological response.</p> <p>Four studies reported data on pathological response defined as the absence of cancer in the breast and axilla. Administering taxanes first resulted in little to no difference in pCR compared to administering anthracyclines first (RR 1.15, 95% CI 0.96 to 1.38; 1280 participants; 4 studies; high‐certainty evidence; <a href="./references#CD012873-fig-0008" title="">Analysis 1.3</a>; <a href="#CD012873-fig-0005">Figure 5</a>); however, there appeared to be a trend in favour of taxanes first. </p> <div class="figure" id="CD012873-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.3 Pathological complete response (pCR) includes by hormone or HER2 receptor status." data-id="CD012873-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.3 Pathological complete response (pCR) includes by hormone or HER2 receptor status. </p> </div> </div> </div> <p>Two studies provided data by hormone receptor or HER2 (or both) status (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). Overall, receptor status did not appear to affect the results (<a href="./references#CD012873-fig-0008" title="">Analysis 1.3</a>); however, <a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a> was confounded with participants receiving trastuzumab throughout the trial period in the taxanes followed by anthracycline treatment arm while the other treatment group received trastuzumab only after receiving anthracyclines. Therefore, results need to be considered cautiously. </p> <p>One study defined pathological response as the absence of invasive or in situ carcinoma in the breast or axillary lymph nodes (<a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a>). Based on one study, administering taxanes first probably resulted in little to no difference in pathological response compared to anthracyclines first (RR 0.93, 95% CI 0.47 to 1.84; 119 participants; <a href="./references#CD012873-fig-0009" title="">Analysis 1.4</a>). </p> <p>Two studies reported data relating to absence of invasive cancer in the breast and found that there was probably little or no difference between groups (RR 0.97, 95% CI 0.79 to 1.20; 306 participants; <a href="./references#CD012873-fig-0009" title="">Analysis 1.4</a>). One study reported data relating to absence of invasive cancer in the axilla and indicated a higher response in the taxane first group compared to anthracycline first group (RR 1.66, 95% CI 1.03 to 2.66; 282 participants; <a href="./references#CD012873-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD012873-sec-0087"> <h5 class="title">Standardised Residual Cancer Burden score</h5> <p>None of the studies reported standardised RCB score.</p> </section> <section id="CD012873-sec-0088"> <h5 class="title">Adverse events</h5> <section id="CD012873-sec-0089"> <h6 class="title">Febrile neutropenia</h6> <p>One study collected data on febrile neutropenia (grade 3) but did not report data separately for each treatment group (<a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). In total, 5/20 women reported grade 3 neutropenic fever. </p> </section> <section id="CD012873-sec-0090"> <h6 class="title">Neutropenia</h6> <p>Four studies collected data on neutropenia (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>); however, only one study reported the data in a useable manner (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>). This was because <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> did not report data separately for each treatment group (i.e. in total, 6/20 women reported grade 3/4 neutropenia); <a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a> and <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> presented the incidence of neutropenia for each drug within each treatment arm and accumulating these data across a treatment arm may lead to double‐counting of toxic events. </p> <p>One study presented usable data (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>). Administering taxanes first probably resulted in little to no difference in risk of neutropenia compared to administering anthracyclines first (RR 1.25, 95% CI 0.86 to 1.82; 280 participants; moderate‐certainty evidence; <a href="./references#CD012873-fig-0010" title="">Analysis 1.5</a>). There were 45 events in 142 participants in the taxane first arm and 35 events in 138 participants in the anthracycline first arm. </p> </section> <section id="CD012873-sec-0091"> <h6 class="title">Cardiac toxicity</h6> <p>One study presented data on cardiac toxicity (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>). Administering taxanes first appeared to result in little to no difference in risk of cardiac toxicity compared to administering anthracyclines first (RR 0.97, 95% CI 0.29 to 3.28; 280 participants; data not shown). The study contributed results with 10 events in 280 participants and notably administered trastuzumab and anthracycline concurrently in the intervention arm. </p> </section> <section id="CD012873-sec-0092"> <h6 class="title">Pulmonary toxicity</h6> <p>One study presented data on pulmonary toxicity (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). Administering taxanes first appeared to result in little to no difference in risk of pulmonary toxicity compared to administering anthracyclines first (RR 3.00, 95% CI 0.12 to 73.43; 828 participants; data not shown). The study reported one event of pneumonia in 828 participants. </p> </section> <section id="CD012873-sec-0093"> <h6 class="title">Neurotoxicity</h6> <p>Three studies collected data on neurotoxicity (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>). However, two studies contributed data for the analysis (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>). <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> did not report data separately for each treatment group (i.e. there was one case of peripheral neuropathy in 20 trial participants). </p> <p>Based on two studies, administering taxanes first may have resulted in little to no difference in risk of neurotoxicity compared to administering anthracyclines first (RR 0.95, 95% CI 0.55 to 1.65; 1108 participants; low‐certainty evidence; <a href="./references#CD012873-fig-0010" title="">Analysis 1.5</a>). Time points and method of assessments for neurotoxicity were unclear and, therefore, the ability of these studies to meaningfully detect neurotoxicity remained unclear. Forty‐nine of 1108 participants reported grade 3 or grade 4 neurosensory difficulties. </p> </section> <section id="CD012873-sec-0094"> <h6 class="title">Haematological malignancy</h6> <p>None of the studies reported haematological malignancy.</p> </section> <section id="CD012873-sec-0095"> <h6 class="title">Treatment‐related death</h6> <p>Two studies reported treatment‐related death. Administering taxanes first appeared to result in little to no difference in the risk of treatment‐related death (RR 1.00, 95% CI 0.06 to 15.93; 1108 participants; <a href="./references#CD012873-fig-0010" title="">Analysis 1.5</a>). There were two treatment‐related deaths in 1108 participants. One death was due to neutropenic sepsis and pneumonia after the third dose of paclitaxel in the taxanes first arm while the other death was due to venous thromboembolism two days after the third dose of epirubicin and cyclophosphamide in the anthracyclines first arm. </p> </section> </section> <section id="CD012873-sec-0096"> <h5 class="title">Treatment adherence</h5> <p>Treatment adherence was reported using measures such as number of participants who received at least a certain percentage of the planned dose, received a certain number of weeks of planned cycles, dose reductions, dose intensity and cycle delivered dose intensity (CCDI). Due to the heterogeneity in reporting treatment adherence, <a href="#CD012873-tbl-0003">Table 1</a> shows the results for the five studies that reported this outcome. Two studies reported dose intensity (<a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>; <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>), but with different measures (i.e. calculated either as percentage of planned dose intensity delivered (<a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a>) or CDDI (<a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a>)). These two studies did not suggest a difference in dose intensity or in CDDI between the two treatment groups. </p> <p>Data could be extracted and presented for the dose reduction outcome. One study reported dose reduction and administering taxanes first probably did not increase the risk of requiring dose reductions (RR 0.81, 95% CI 0.59 to 1.11; 280 participants; moderate‐certainty evidence; <a href="./references#CD012873-fig-0011" title="">Analysis 1.6</a>) (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>). </p> </section> <section id="CD012873-sec-0097"> <h5 class="title">Quality of life</h5> <p>None of the studies reported data on quality of life.</p> </section> </section> <section id="CD012873-sec-0098"> <h4 class="title">Adjuvant setting</h4> <p>Four included studies (six records) referring to five treatment comparisons in the adjuvant setting (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). See: <a href="./full#CD012873-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012873-sec-0099"> <h5 class="title">Overall survival</h5> <p>None of the studies presented data for overall survival. One study collected data but reported no results (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). </p> </section> <section id="CD012873-sec-0100"> <h5 class="title">Disease‐free survival</h5> <p>None of the studies presented data for disease‐free survival. One study collected data but reported no results (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). </p> </section> <section id="CD012873-sec-0101"> <h5 class="title">Adverse events</h5> <section id="CD012873-sec-0102"> <h6 class="title">Febrile neutropenia</h6> <p>All four studies, involving five treatment comparisons, reported febrile neutropenia. Administration of taxanes first probably resulted in little to no difference in the risk of febrile neutropenia (RR 0.70, 95% CI 0.24 to 2.05; 4 studies with 5 treatment comparisons; 279 participants; moderate‐certainty evidence; <a href="./references#CD012873-fig-0012" title="">Analysis 2.1</a>). There were four cases of febrile neutropenia in 142 participants in the taxanes first arm and six cases of febrile neutropenia in 137 participants in the anthracyclines first arm. </p> </section> <section id="CD012873-sec-0103"> <h6 class="title">Neutropenia</h6> <p>All four studies, involving five treatment comparisons, reported neutropenia (grade 3/4). Administration of taxanes first reduced the risk of grade 3/4 neutropenia when compared with anthracyclines first (RR 0.62, 95% CI 0.40 to 0.97; 4 studies with 5 treatment comparisons; 279 participants; high‐certainty evidence; <a href="./references#CD012873-fig-0012" title="">Analysis 2.1</a>). There were 23 events in 142 participants in the taxane first arm and 35 events in 137 participants in the anthracyclines first arm. </p> </section> <section id="CD012873-sec-0104"> <h6 class="title">Cardiac toxicity</h6> <p>Two studies reported cardiac toxicity. Administration of taxanes first probably resulted in little to no difference in the risk of cardiac toxicity (RR 0.30, 95% CI 0.01 to 6.99; 2 studies; 120 participants; moderate‐certainty evidence; data not shown). There were no events in the taxane first group and one event in the anthracyclines first group in a total of 120 participants. </p> </section> <section id="CD012873-sec-0105"> <h6 class="title">Pulmonary toxicity</h6> <p>One study reported pulmonary toxicity. Administration of taxanes first may have resulted in little to no difference in the risk of pulmonary toxicity (RR 0.33, 95% CI 0.01 to 7.85; 56 participants; moderate‐certainty evidence; data not shown). There were no events in the taxane first arm and one event in the anthracyclines first arm in a total of 56 participants. </p> </section> <section id="CD012873-sec-0106"> <h6 class="title">Neurotoxicity</h6> <p>Three studies reported data for neurotoxicity. Administration of taxanes first may have resulted in little to no difference in the risk of neurotoxicity (RR 0.78, 95% CI 0.25 to 2.46; 162 participants; 3 studies; low‐certainty evidence; <a href="./references#CD012873-fig-0012" title="">Analysis 2.1</a>). There were four events in 83 participants in the taxane first arm and five events in 79 participants in the anthracyclines first arm. </p> </section> <section id="CD012873-sec-0107"> <h6 class="title">Haematological malignancy</h6> <p>None of the studies reported haematological malignancy.</p> </section> <section id="CD012873-sec-0108"> <h6 class="title">Treatment‐related death</h6> <p>One study reported treatment‐related death. There were no events in either group (64 participants; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). </p> </section> </section> <section id="CD012873-sec-0109"> <h5 class="title">Treatment adherence</h5> <p>Treatment adherence was reported using a variety of measures. These included dose delays, dose reductions, one‐dose reductions, number of participants who did not receive the planned number of cycles (i.e. six or eight cycles) and dose intensity. The available data have been presented separately below. </p> <section id="CD012873-sec-0110"> <h6 class="title">Delay in treatment</h6> <p>Three studies involving four treatment comparisons reported delay in treatment (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). Administration of taxanes first probably resulted in little to no difference in the risk of dose delays (RR 0.76, 95% CI 0.52 to 1.12; 238 participants; 3 studies with 4 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD012873-fig-0013" title="">Analysis 2.2</a>). There were 31 dose delays in 121 participants in the taxane first arm compared to 39 dose delays in 117 participants in the anthracycline first arm. </p> </section> <section id="CD012873-sec-0111"> <h6 class="title">Dose reduction</h6> <p>Two studies involving three treatment comparisons reported dose reductions (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). For the taxane component (docetaxel), the taxane first regimen probably reduced the number of dose reductions compared to anthracyclines first regimen (RR 0.33, 95% CI 0.15 to 0.73; 173 participants; 3 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD012873-fig-0014" title="">Analysis 2.3</a>.1). Seven dose reductions occurred in 87 participants in the taxane first arm compared to 21 dose reductions in 86 participants in the anthracycline first taxane arm. For the anthracycline component (fluorouracil, epirubicin, cyclophosphamide), the taxane first regimen probably resulted in little to no difference in the number of dose reductions compared to anthracyclines first regimen (RR 0.98, 95% CI 0.18 to 5.44; 117 participants; 1 study, 2 treatment comparisons; moderate‐certainty evidence; <a href="./references#CD012873-fig-0014" title="">Analysis 2.3</a>.2). </p> </section> <section id="CD012873-sec-0112"> <h6 class="title">One‐dose reduction</h6> <p>One study reported data on one‐dose reduction (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). Administration of taxanes first probably resulted in little to no difference in the number of one‐dose reductions compared to the anthracyclines first regimen (RR 0.55, 95% CI 0.14 to 2.10; 65 participants; <a href="./references#CD012873-fig-0015" title="">Analysis 2.4</a>). </p> </section> <section id="CD012873-sec-0113"> <h6 class="title">Did not receive planned cycles</h6> <p>Three studies reported data on participants who did not receive planned cycles (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Administration of taxanes first probably resulted in little to no difference in the number of planned cycles received (RR 0.45, 95% CI 0.15 to 1.31; 163 participants; <a href="./references#CD012873-fig-0016" title="">Analysis 2.5</a>). There were 4/83 participants who did not receive the planned number of cycles in the taxane first arm compared to 9/80 participants in the anthracycline first arm. </p> </section> <section id="CD012873-sec-0114"> <h6 class="title">Dose intensity</h6> <p>Four studies involving five treatment comparisons reported data on dose intensity (<a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a>; <a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; <a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>; Wildiers (<a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a>; <a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a>)). However, the presentation of data varied across the studies and only one study reported a measure of precision (in the form of a CI, standard error or standard deviation) (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>; median and range). Therefore, data could not be pooled using meta‐analysis. The results for all studies are provided in <a href="#CD012873-tbl-0004">Table 2</a>. Overall, the relative dose intensity (a percentage of the absolute dose intensity (actual) divided by the planned dose intensity) indicated that the taxane component within the taxanes first arm was possibly more likely to meet the expected dose compared to the anthracyclines first arm. When examining the anthracycline component of the chemotherapy schedule, the mean relative dose intensity may have been more likely to meet the expected dose in the anthracycline first arm than the taxane first arm. </p> </section> </section> <section id="CD012873-sec-0115"> <h5 class="title">Quality of life</h5> <p>One study reported quality of life data using the Functional Assessment of Cancer Therapy – Breast Cancer (FACT‐B) version 4 questionnaire (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Scores were similar in both groups for a subset of 20 participants who were assessed before, during and after treatment. Numerical or further details were not provided in the trial publication. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012873-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012873-sec-0116">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012873-sec-0181">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012873-sec-0116"></div> <section id="CD012873-sec-0117"> <h3 class="title" id="CD012873-sec-0117">Summary of main results</h3> <p>In the neoadjuvant setting, there is likely to be no or little difference in survival outcomes, tumour response or toxicity due to the sequence in which anthracyclines and taxanes are delivered. There was no evidence of either significant benefit or harm; however, the number of studies and participants contributing data were small. We expect the collection of data over time to provide further information regarding survival outcomes. </p> <p>In the adjuvant setting, there were no available survival data. There is high‐ to low‐certainty evidence in regard to the differences in toxicity between the two regimens. Sequencing taxanes first reduced the risk of grade 3 or grade 4 neutropenia with no differences observed for other toxicities. Administering taxane first likely reduced the risk of requiring dose reductions for taxanes. The ability to deliver taxanes with reduced need for dose reductions may result in an important benefit if it improves survival; however, data regarding survival were lacking. </p> <p>With the available data, there was no strong evidence for harm, benefit or equivalence due to the order in which taxane was delivered and, therefore, the specific clinical situation may take precedence when choosing the chemotherapy regimen. </p> </section> <section id="CD012873-sec-0118"> <h3 class="title" id="CD012873-sec-0118">Overall completeness and applicability of evidence</h3> <p>Only two neoadjuvant studies reported on our primary outcome of overall survival and one on our secondary outcome of disease‐free survival. Two further studies collected survival data (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>; <a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a>), and the reporting from one is awaited (<a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a>). No adjuvant study reported on survival outcomes and only one study collected data (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). Most were feasibility studies assessing toxicities. We suspect that a wider range of toxicity data, including important and routinely assessed toxicities such as febrile neutropenia and neurotoxicities were probably collected but not reported in the publications. None of the studies included numerical data for quality of life. Some studies had only a small subset of people with reported HER2‐positive or triple negative disease. Overall, the review had limited generalisability as the studies may not have included all relevant types of participants and there was limited information for some important outcomes. </p> <p>The results of this review do not provide sufficient evidence to recommend a change from current local practice. </p> </section> <section id="CD012873-sec-0119"> <h3 class="title" id="CD012873-sec-0119">Quality of the evidence</h3> <p>Overall, the certainty of the evidence across the two settings was high to low. There were five neoadjuvant studies with 1415 participants and four adjuvant studies with 280 participants. The studies were open‐label, which potentially increases the risk of bias for toxicity and quality of life domains; however, we judged this risk to be small as all arms were receiving the same drugs. Otherwise, methodologically the studies were well conducted overall. <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> contributed the most data to the meta‐analysis and was a well‐reported study. In general, due to imprecision it was difficult to judge consistency of results as the CIs were wide and overlapping. Studies did not consistently report or collect data on the review's outcomes and with the smaller number of studies the optimal information size was not met. In addition, in some cases, length of follow‐up was short or not reported. </p> </section> <section id="CD012873-sec-0120"> <h3 class="title" id="CD012873-sec-0120">Potential biases in the review process</h3> <p>The aim of this review was to provide a thorough assessment of any important risks and benefits due to the sequence in which anthracyclines and taxanes are administered, in an adjuvant or neoadjuvant setting. Despite a comprehensive search of the databases and key conferences we may not have identified all potentially relevant studies. Studies may have used a sequenced regimen without investigation of the effect of the sequence in which taxanes are delivered being an objective. These studies potentially may have been excluded in the title and abstract review. </p> <p>Due to the number of studies, we did not examine the funnel plot to assess reporting bias. Small negative studies are included in this review; however, there may be further such studies that have not been published. Only one study has not reported on collected survival data which should have been available since initial publication (<a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a>). We contacted the study authors to determine if there were data collected but not reported and for clarification of data, but received no response. Overall, we judged the risk of publication bias to be low. </p> <p>There are a few minor amendments between our protocol and review which we made to include more relevant studies (docetaxel every 14 days) or report on more information (neutropenia) or for ease of organisation of information (pathological response rather than degree of response). We do not believe that these amendments would have introduced bias. </p> <p>It is possible that not all of the studies that exist on this topic have been included in this review. Many of the titles and abstracts retrieved provided no indication that they examined sequencing of chemotherapy. The reference lists of existing systematic reviews and included studies were used to cross‐check whether all potentially relevant studies were included in this Cochrane Review. We welcome contact from trial authors who note that their trial is missing from this review. </p> </section> <section id="CD012873-sec-0121"> <h3 class="title" id="CD012873-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>This review complements a prior review that included retrospective and non‐randomised studies and did not pool data (<a href="./references#CD012873-bbs2-0032" title="BinesJ , EarlH , BuzaidAC , SaadED . Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Annals of Oncology2014;25(6):1079‐85. ">Bines 2014</a>). Since that review, results for one study have become available (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). In our analysis administering taxane probably did not result in any meaningful difference in pathological response. We agree with the authors that the reverse sequence administering taxane first is an acceptable option. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012873-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012873-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012873-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.1 Overall survival." data-id="CD012873-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.2 Disease‐free survival." data-id="CD012873-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Neoadjuvant, outcome: 1.3 Pathological complete response (pCR) includes by hormone or HER2 receptor status." data-id="CD012873-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Neoadjuvant, outcome: 1.3 Pathological complete response (pCR) includes by hormone or HER2 receptor status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 1 Overall survival." data-id="CD012873-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 2 Disease‐free survival." data-id="CD012873-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 3 Pathological complete response (pCR) includes by hormone or HER2 receptor status." data-id="CD012873-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 3 Pathological complete response (pCR) includes by hormone or HER2 receptor status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 4 Pathological response." data-id="CD012873-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 4 Pathological response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 5 Adverse events." data-id="CD012873-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Neoadjuvant, Outcome 6 Treatment adherence: dose reduction." data-id="CD012873-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Neoadjuvant, Outcome 6 Treatment adherence: dose reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adjuvant, Outcome 1 Adverse events." data-id="CD012873-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Adjuvant, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adjuvant, Outcome 2 Treatment adherence: delay in treatment." data-id="CD012873-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Adjuvant, Outcome 2 Treatment adherence: delay in treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adjuvant, Outcome 3 Treatment adherence: dose reduction." data-id="CD012873-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Adjuvant, Outcome 3 Treatment adherence: dose reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adjuvant, Outcome 4 Treatment adherence: one‐dose reduction." data-id="CD012873-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Adjuvant, Outcome 4 Treatment adherence: one‐dose reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012873-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/urn:x-wiley:14651858:media:CD012873:CD012873-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_t/tCD012873-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adjuvant, Outcome 5 Treatment adherence: did not receive planned cycles." data-id="CD012873-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Adjuvant, Outcome 5 Treatment adherence: did not receive planned cycles.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/media/CDSR/CD012873/image_n/nCD012873-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012873-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> neoadjuvant therapy for early breast cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane followed by anthracyclines<br/> <b>Comparison:</b> anthracyclines followed by taxane </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anthracyclines followed by taxane</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane followed by anthracyclines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> (follow‐up: up to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>3‐year risk of death</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.80</b><br/> (0.60 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>947<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<br/> (516 to 729) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disease‐free survival</b><br/> (follow‐up: up to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>3‐year risk of recurrence</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.84</b><br/> (0.65 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>828<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>552 per 1000<br/> (463 to 648) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pathological complete response</b> (no invasive cancer in breast or axilla) </p> <p>(follow‐up: up to 5 years for 2 studies; unreported in 2 studies)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/> (0.96 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1280<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/> (219 to 314) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neutropenia</b> (grade 3/4) </p> <p>(follow‐up: up to 6 months based on number of chemotherapy cycles)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/> (0.86 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>280<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1000<br/> (218 to 462) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neurotoxicity</b> (grade 3/4) </p> <p>(follow‐up: up to 5 or 6 months based on number of chemotherapy cycles)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b><br/> (0.55 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1108<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/> (25 to 75) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment adherence</b> (defined as dose reduction) </p> <p>(follow‐up: up to 6 months based on number of chemotherapy cycles)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.81</b><br/> (0.59 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>280<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>399 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>323 per 1000<br/> (235 to 442) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The baseline risk in the anthracycline followed by taxane group was based on risk estimates provided in <a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> (Figure 2D for overall survival; Figure 2B for disease‐free survival).<br/> <sup>b</sup>The number of events did not meet the optimal information size (approximately 120 events in total in one study) and only one study reported follow‐up of five years for overall survival. Therefore, we downgraded by one level for both imprecision and indirectness.<br/> <sup>c</sup>The optimal information size was not met (as per GRADE guidance; <a href="./references#CD012873-bbs2-0041" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64:1283‐93. ">Guyatt 2011</a>). Therefore, we downgraded by one level for imprecision only.<br/> <sup>d</sup>We did not downgrade for imprecision as the optimal information size was met.<br/> <sup>e</sup>The confidence intervals were very wide, indicating no effect and appreciable benefit and harm with taxanes first. Therefore, we downgraded by one level for imprecision.<br/> <sup>f</sup>The confidence intervals were very wide and the impact of unblinding on the assessment of neurotoxicity was unclear. Therefore we downgraded by one level for imprecision and one level for risk of bias.<br/> <sup>g</sup>The optimal information size was not met (as per GRADE guidance; <a href="./references#CD012873-bbs2-0041" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64:1283‐93. ">Guyatt 2011</a>), and the impact of unblinding on treatment adherence was unclear. Therefore, we downgraded by one level only for imprecision and risk of bias. We did not think that risk of bias was very serious due to the design of the studies whereby participants received both treatment drugs but in a different order; therefore, we deducted 0.5 levels for risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in neoadjuvant therapy for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012873-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adjuvant therapy for early breast cancer<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane followed by anthracyclines<br/> <b>Comparison:</b> anthracyclines followed by taxane </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anthracyclines followed by taxane</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane followed by anthracyclines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disease‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neutropenia (grade 3/4)</b> </p> <p>(follow‐up: up to 3.5 or 4.5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.6</b>2<br/> (0.40 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>279<br/> (4 RCTs, 5 treatment comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>High</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000<br/> (102 to 248) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: neurotoxicity (grade 3/4)</b> </p> <p>(follow‐up: up to 4 or 4.5 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b><br/> (0.25 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (16 to 156) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment adherence</b> (defined as dose delay) </p> <p>(follow‐up: up to 3.5 or 4.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b><br/> (0.52 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238<br/> (3 RCTs, 4 treatment comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/> (173 to 373) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(follow‐up: up to 4 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported quality of life data using the FACT‐B version 4 questionnaire (<a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a>). Scores were similar in both groups for a subset of 20 participants who were assessed before, during and after treatment. Numerical or further details were not provided in the trial publication. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade the certainty of the evidence. A lack of blinding was judged to be unlikely to influence physician assessment of grade 3/4 neutropenia (blood tests) and there was no heterogeneity detected across studies.<br/> <sup>b</sup>The confidence intervals were very wide and the impact of unblinding on the assessment of neurotoxicity was unclear. Therefore, we downgraded by one level for imprecision and one level for risk of bias.<br/> <sup>c</sup>The study was open‐label with no independent assessment of this outcome. We did not think that the risk of bias was overly serious due to the design of the study where participants received both treatment drugs but in a different order. The confidence intervals were wide and the optimal information size was not meet. Therefore, we downgraded by one level for both imprecision and risk of bias.<br/> <sup>d</sup>Information for this outcome derived from a very small sample size (from one study). Therefore, we downgraded by one level due to imprecision. We did not downgrade for risk of bias despite this being an open‐label study. This is because all participants received the same treatment though in a different order and this was unlikely to influence participant‐reported responses. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Taxane followed by anthracyclines compared to anthracyclines followed by taxane in adjuvant therapy for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012873-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment adherence measures for neoadjuvant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adherence measure reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane followed by anthracycline (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline followed by taxane (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012873-bbs2-0002" title="BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T FEC+T) in HER2+ operable breast cancer. Lancet2013;14:1317‐25. BuzdarA , SumanVJ , Meric‐BernstamF , LeitchAM , EllisMJ , BougheyJC , et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T → FEC + T) in HER2+ operable breast cancer. Journal of Clinical Oncology2013;15(Suppl):502. ">ACOSOG Z1041 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who received ≥ 90% of planned dose of paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121/142 (85.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124/138 (89.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants who received ≥ 90% of planned dose of FEC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123/142 (86.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103/138 (74.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Received ≥ 20 weeks of the planned 24 weeks of trastuzumab<sup>a</sup> or ≥ 10 weeks of planned 12 weeks of trastuzumab<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127/142 (89.4%)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126/138 (91.3%)<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose reductions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/142 (32.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/138 (39.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinued due to intolerance (severe toxic effects)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/142 (6.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/138 (6.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0004" title="ACTRN12605000588695 . Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: evaluation of biological, clinical and imaging markers of tumour response. anzctr.org.au/trial/registration/ANTRN12605000588695 (first received 21 September 2005). AlamgeerM , GanjuV , KumarB , FoxJ , HartS , WhiteM , et al. Changes in aldehyde dehydrogenase‐1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research2014;16:R44. ">Alamgeer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0005" title="MillerKD , SouleSE , CalleyC , EmersonRE , HutchinsGD , KopeckyK , et al. Randomized phase II trial of the anti‐angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Research and Treatment2005;89:187‐97. ">Miller 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose intensity<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane: 97.%</p> <p>Doxorubicin: 94.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin: 95.2%</p> <p>Taxane: 89.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012873-bbs2-0006" title="EarlHM , VallierAL , HillerL , FenwickN , YoungJ , IddawelaM , et al. Effects of the addition of gemcitabine, and paclitaxel‐first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high‐risk early breast cancer (Neo‐tAnGo): an open‐label, 2×2 factorial randomised phase 3 trial. Lancet Oncology2014;15:201‐12. NCT00070278 . Neoadjuvant epirubicin, cyclophosphamide, and paclitaxel with or without gemcitabine in treating women who are undergoing surgery for early breast cancer. clinicaltrials.gov/show/NCT00070278 (first received 7 October 2003). ">Neo‐TAnGo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cycle delivered dose intensity<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of cycles with dose reductions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane → epirubicin: 3%<br/> Taxane + gemcitabine → epirubicin: 5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin → taxane: 6%<br/> Epirubicin + gemcitabine → taxane: 9% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of cycles with dose delays</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taxane → epirubicin: 15%<br/> Taxane + gemcitabine → epirubicin: 15% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epirubicin → taxane: 15%<br/> Epirubicin + gemcitabine → taxane: 16% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0008" title="StearnsV , SinghB , TsangarisT , CrawfordJG , NovielliA , EllisMJ , et al. 2003. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer2003;9:124‐33. ">Stearns 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>FEC: fluorouracil, epirubicin and cyclophosphamide; n: number of participants with delay or dose reduction, etc; N: denominator; NR: not reported. </p> <p><sup>a</sup>≥ 20 weeks of the planned 24 weeks of trastuzumab.<br/> <sup>b</sup>≥ 10 weeks of planned 12 weeks of trastuzumab.<br/> <sup>c</sup>Calculated as percentage of planned dose intensity delivered<br/> <sup>d</sup>Calculated as mean of the individual drug delivered dose intensities planned for that cycle; course drug delivered dose as mean of course drug delivered doses over planned number of cycles, per participant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment adherence measures for neoadjuvant studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012873-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dose intensity data for adjuvant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term used to represent dose intensity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Taxane followed by anthracycline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anthracycline followed by taxane </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0001" title="AbeH , MoriT , KawaiY , ChoH , KubotaY , UmedaT , et al. Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. International Journal of Clinical Oncology2013;18:487‐91. ">Abe 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean relative dose intensity<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 95.2%</p> <p>FEC: 98.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 94.2%</p> <p>FEC: 97.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0003" title="PiedboisP , SerinD , PriouF , LaplaigeP , GregetS , AngellierE , et al. Dose‐dense adjuvant chemotherapy in node‐positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology2007;18:52‐7. ">AERO B03 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median relative dose intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 96% (range: 25–104)</p> <p>Epirubicin: 96% (range: 0–102)</p> <p>Cyclophosphamide: 95% (range: 0–102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 81% (range: 0–102)</p> <p>Epirubicin: 97% (range: 66–102)</p> <p>Cyclophosphamide: 97% (range: 61–102)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0007" title="NCT00201708 . Dose‐dense docetaxel before or after doxorubicin/cyclophosphamide in axillary node‐positive breast cancer. clinicaltrials.gov/show/NCT00201708 (first received 20 September 2005). PuhallaS , MrozekE , YoungD , OttmanS , McVeyA , KendraK , et al. Randomized phase II adjuvant trial of dose‐dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node‐positive breast cancer. Journal of Clinical Oncology2008;26(10):1691‐7. ">Puhalla 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean relative dose intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 96%</p> <p>Doxorubicin: 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 82%</p> <p>Doxorubicin: 96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0009" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean dose intensity<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 99%</p> <p>FEC: 97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 97%</p> <p>FEC: 97%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012873-bbs2-0010" title="WildiersH , DirixL , NevenP , ProvéA , ClementP , AmantF , et al. Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose‐dense FEC and docetaxel – results of a randomized, open‐label phase II study. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13‐16; San Antonio (TX). 2007; Vol. S150:3072. WildiersH , DirixL , NevenP , ProvéA , ClementP , SquiffletP , et al. Delivery of adjuvant sequential dose‐dense FEC‐Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment2009;114:103‐12. ">Wildiers 2009b</a> (dose‐dense) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean dose intensity<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 111%</p> <p>FEC: 143%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Docetaxel: 108%</p> <p>FEC: 146%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>FEC: fluorouracil, epirubicin, cyclophosphamide.</p> <p><sup>a</sup>Data used based on the reporting of findings in the abstract and Table 2 in the trial publication. The docetaxel and FEC percentages were switched in the text in the Results section. Therefore, the consistency of results presented in Table 2 and abstract were considered to be the most accurate reflection of the results. </p> <p><sup>b</sup>Defined as the dose intensity achieved in intervention or comparator arm for a participant who received all intended doses with no cycle delay or dose reduction. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Dose intensity data for adjuvant studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/full#CD012873-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012873-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Neoadjuvant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pathological complete response (pCR) includes by hormone or HER2 receptor status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No invasive cancer in breast or axilla</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.96, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oestrogen receptor (ER)‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.88, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 ER‐negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.89, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 HER2‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 HER2‐negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.92, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 HER2‐negative, ER‐negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.77, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pathological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 No invasive or in situ carcinoma in breast or axilla</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.47, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 No invasive cancer in breast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 No invasive cancer in axillary lymph nodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.03, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.86, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Neurotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Treatment‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Treatment adherence: dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Neoadjuvant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012873-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Febrile neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.24, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Neurotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.25, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Treatment‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Treatment adherence: delay in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.52, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment adherence: dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Taxane (docetaxel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.15, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Anthracycline combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.18, 5.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Treatment adherence: one‐dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.14, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Treatment adherence: did not receive planned cycles <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.15, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012873.pub2/references#CD012873-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012873.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012873-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012873-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012873-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD012873-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012873-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012873-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012873-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012873\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012873\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012873\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012873\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012873\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012873.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012873.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012873.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012873.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012873.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726873962"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012873.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726873966"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012873.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9e471a42f480',t:'MTc0MDcyNjg3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 